EP0000473A1 - Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives - Google Patents

Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives Download PDF

Info

Publication number
EP0000473A1
EP0000473A1 EP78100207A EP78100207A EP0000473A1 EP 0000473 A1 EP0000473 A1 EP 0000473A1 EP 78100207 A EP78100207 A EP 78100207A EP 78100207 A EP78100207 A EP 78100207A EP 0000473 A1 EP0000473 A1 EP 0000473A1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
amino
desamino
desaminogentamicin
antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78100207A
Other languages
German (de)
French (fr)
Other versions
EP0000473B1 (en
Inventor
Peter Daniels
Stuart Mccombie
Nagabhushan L. Tattanahalli
Jay Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD International Holdings GmbH
Scherico Ltd
Original Assignee
Scherico Ltd
Technobiotic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherico Ltd, Technobiotic Ltd filed Critical Scherico Ltd
Publication of EP0000473A1 publication Critical patent/EP0000473A1/en
Application granted granted Critical
Publication of EP0000473B1 publication Critical patent/EP0000473B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to a process for preparing 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols having a 6'-amino function and pharmaceutically acceptable acid addition salts thereof, to novel compounds and salts obtained by this process; and to novel antibacterially active compositions comprising such novel compounds or salts.
  • 4,6-Di-O-(aminoglycosyl)-1,3-diaminocyclitols are generally known in the art. Some of these, e.g. kanamycin A, gentamicin B and gentamicin B 1 have a 2'-hydroxy-group and a 6'-amino function. They are, however, obtained microbiologically, e.g. gentamicin B and B 1 are coproduced with the gentamicin C complex during the fermentation of certain species of the genus Micromonospora, e.g. M. purpurea as described in U.S. Patents No.
  • kanamycin is produced microbiologically by the fermentation of certain species of the genus Streptomyces, e.g. S. kanamyceticus as described in U.S. Patent No. 2,931,798.
  • the process of this invention provides a chemical method for preparing novel 2'-hydroxy-2'-desamino-4,6-di-O-(aminogly- cosyl)-1,3-diaminocyclitols having antibacterial activity which cannot be obtained via prior art microbiological methods.
  • the process provides a novel method for preparing known compounds, e.g. gentamicin B (which.is obtained in poor yields, i.e. less than about 10 %, when prepared microbiologically) by converting the known Antibiotic JI-20A into 2'-hydroxy-2'-desamino-Antibiotic JI-20A which has the same structure as gentamicin B.
  • known compounds e.g. gentamicin B (which.is obtained in poor yields, i.e. less than about 10 %, when prepared microbiologically) by converting the known Antibiotic JI-20A into 2'-hydroxy-2'-desamino-Antibiotic JI-20A which has the same structure as gentamicin B.
  • the antibiotics gentamicin C 1 , C 1a' C 2' C 2a' C 2b' si so crdamicin, Antibiotic G-52, Antibiotic 66-40B, Antibiotic 66-40D, Antibiotic JI-20B, tobramycin, 3',4'-dideoxykanamycin B, Antibiotic Mu-1 and Antibiotic Mu-4, as well as Antibiotic JI-20A (which may be converted into gentamicin B by the process of this invention) may be illustrated by the following formula I whereby, for the various antibiotics listed above, the "substituents" a, b, c, d, f, g, h, i, m, o and p as well as the bond between C4' and C5' are as given in the table be- low.
  • substituents contemplated for the grouping CH 2 X referred to above are straight and branched chain alkyl groups such as ethyl, n-propyl, n-butyl, 0-methylpropyl; cycloalkyl groups such as cyclopropylmethyl; alkenyl groups such as ⁇ -propenyl, ⁇ -methylpropenyl, ⁇ -butenyl; hydroxy substituted straight and branched chain alkyl groups such as ⁇ -hydroxy- ⁇ -methylbutyl, ⁇ -hydroxy- ⁇ -methylpropyl, a-hydroxybutyl, ⁇ -hydroxypropyl, ⁇ -hydroxypropyl; amino substituted straight and branched chain alkyl groups such as ⁇ -aminopropyl, ⁇ -aminopropyl, a-aminobutyl, and mono-N-alkylated derivatives thereof such as the N-methyl and N-ethyl derivatives, e.g.
  • ⁇ -methylaminopropyl amino and hydroxy disubstituted straight and branched chain alkyl groups such as ⁇ -hydroxy- ⁇ -aminobutyl, ⁇ -hydroxy- ⁇ -aminopropyl, and ⁇ -hydroxy- ⁇ -methyl- ⁇ -aminopropyl; and mono-N-alkylated derivatives thereof such as ⁇ -hydroxy- ⁇ -ethylaminopropyl.
  • substituents for the moiety CH 2 X preferred are ethyl, n-propyl and ⁇ -aminobutyl.
  • the 1-N-( ⁇ -amino- ⁇ -hydroxy) substituent in the foregoing 1-N-( ⁇ -amino- ⁇ -hydroxy)-2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols may be in the R,S- form or in the R- form or in the S- form.
  • each of the foregoing names includes all three forms.
  • the name 1-N-( ⁇ -amino- ⁇ -hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin Cla includes 1-N-(S- ⁇ amino- ⁇ -hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C 1a , 1-N-(R- ⁇ amino- ⁇ -hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C 1a and 1-N-(R,S- ⁇ -amino- ⁇ -hyaroxy- butyryl)-2'-hydroxy-2'-desaminogentamicin C 1a .
  • the pharmaceutically acceptable acid addition salts of this invention may be prepared according to known procedures such as by neutralizing the free base with the appropriate acid, usually to about pH 5.
  • Preferred acids for this purpose are hydrochloric, sulfuric, phosphoric and hydrobromic acid.
  • the acid addition salts are white solids which are soluble in water and insoluble in most polar and nonpolar organic solvents.
  • the process of this invention for the preparation of a 2'- liydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol having an amino function in position 6' is characterised in that the corresponding 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol having an amino function in position 2' wherein all other amino functions are protected by a protecting group, is oxidized by means of hydrogen peroxide in an inert solvent in the presence of tungstate ion at a pH of about 9 to about 11, whereby the molar ratio of hydrogen peroxide to starting compound is at least 2:1, that the so-obtained 2'-oximino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol is subjected to a cleavage of the oxime function; that the so-obtained 2
  • the oxidation is usually carried out at room temperature in aqueous methanol, although other lower alkanols, e.g. ethanol and isopropanol, are conveniently employed.
  • aqueous methanol although other lower alkanols, e.g. ethanol and isopropanol, are conveniently employed.
  • any organic solvent which will dissolve the aminoglycoside and which does not react with hydrogen peroxide e.g. dimethylacetamide, dimethylformamide, tetrahydrofuran, dioxan and diglyme may be used.
  • the pH of the reaction mixture be maintained between 9 and 11 (preferably at pH 10 to pH 10.5), e.g. by addition of a base (sodium hydroxide), in order to minimize side reactions occurring such as glycoside cleavage and protonation of the amine.
  • a base sodium hydroxide
  • reaction is continued until almost all the amino function is consumed as determined by thin layer chromatographic techniques, then the resulting 2'-oximino-N-protected-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol intermediate is isolated as a mixture of syn and anti isomers utilizing known techniques (e.g. extraction and chromatographic techniques).
  • the 2'-oximino-N-protected -4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol prepared as described above is cleaved to the corresponding 2'-oxo derivative utilizing known techniques for cleaving oximes.
  • the cleaving of the 2'-oximino function is achieved by an acidic hydrolytic medium in the presence of acetaldehyde (e.g.
  • Reduction of the 2'-oxo-N-protected aminoglycoside intermediate in the third step is preferentially carried out by reaction with an alkali metal borohydride (usually sodium borohydride) according to known procedures for reducing a keto group to a hydroxyl function, and there is obtained an excellent yield of N-protected-2'-hydroxy-2'-desamino-aminoglycoside in which the 2'-hydroxyl function is in the equatorial position, i.e. the same stereoconfiguration as the starting 2'-amino function.
  • an alkali metal borohydride usually sodium borohydride
  • the 2'-amino function in a 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol can be replaced by a hydroxyl group via the process of this invention, then other functions may be introduced into the 2'-hydroxy-2'-desamino-aminoglycoside by methods known in the art.
  • This alternate method is the method of choice when preparing the preferred 1-N-( ⁇ -amino- ⁇ -hydroxyalkanoyl)-2'-hydroxy-2'-desamino derivatives of this invention.
  • a preferred method involves first converting gentamicin C 1a to 2'-hydroxy-2'-desaminogentamicin C 1a via the process of this invention, and thence converting 2'-hydroxy-2'-desaminogentamicin C 1a to the 1-N-(S- ⁇ -amino- ⁇ -hydroxypropionyl)- or the 1-N-(S- ⁇ -amino- ⁇ -hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C la utilizing techniques known in the art and as described in the examples.
  • Typical starting compounds are the 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol antibacterial agents described by formula I in combination with Table I above.
  • Particularly useful starting antibiotic precursors are sisomicin and gentamicin C 1a which lead to preferred 2'-hydroxy-2'-amino derivatives of this invention, and Antibiotic JI-20A which leads to gentamicin B.
  • antibiotic precursors include 5-epi-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol antibacterials described in U.S. Patent No. 4,000,261; 5-epi-azido-5-deoxy-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol antibacterials described in U.S. Patent No. 4,000,262; l-N-alkyl-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol antibacterials described in U.S. Patent No.
  • a 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol of this invention may be converted to a corresponding 1-N-alkyl derivative or to a corresponding 5-deoxy-, or a 5-epi- or 5-epi-azido-5-deoxy derivative, via procedures analogous to those described in the above-mentioned patents.
  • a 2'-hydroxy-2'-desamino-4,6-di-O-(amino- glycosyl)-2-deoxystreptamine of this invention (e.g. 2'-hydroxy-2'-desaminosisomicin) is converted to the corresponding 5-deoxy derivative (e.g. 2'-hydroxy-2'-desamino-5-deoxysisomicin) by first converting said 2'-hydroxy-2'- desamino-4,6-di-O-(aminoglycosyl)-2-deoxystreptamine to the corresponding N- and 0-protected (except for the 5-hydroxyl group) intermediate (e.g.
  • a 2'-hydroxy-2'-dQSamino-4,6-di-O-(aminoglycosyl)-2-deoxystreptamine of this invention is converted to the corresponding 5-epi-fluoro-5-deoxy derivative according to procedures analogous to those described in South African Patent No. 78/0385, whereby an N- and O-protected-2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-2-deoxystreptamine having a free 5-hydroxyl group (e.g.
  • 1,3,6'-tri-N-benzyloxycarbonyl-2',2"-di-Obenzoyl-3",4"-N,0-carbonyl-2'-hydroxy-2'-desaminosisomicin) is reacted with a dialkylaminosulfur trifluoride, preferably diethylaminosulfur trifluoride in methylene chloride, followed by treatment with sodium bicarbonate and then removal of the N- and 0-protecting groups to obtain a 5-epi-fluoro-2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-2,5-dideoxystreptamine of this invention (e.g. 5-epi-fluoro-2'-hydroxy-2'-desamino-5-deoxysisomicin).
  • a dialkylaminosulfur trifluoride preferably diethylaminosulfur trifluoride in methylene chloride
  • N-protected starting compounds of our process wherein all amino functions except the 2'-amino group in a 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol are protected by groups susceptible to reductive cleavage or basic hydrolysis, are conveniently prepared by combining procedures known in the art, together with a selective blocking procedure described in Belgian Patent No. 855704.
  • a transition metal salt complex between available neighboring amino and hydroxyl functions in said 4,6-di-O-(aminoglycosyl)-1,3-diamtnocyclitol and cupric acetate or nickel (II) acetate is first prepared followed by introduction of acyl functions on non-complexed and/or weakly complexed amino functions, and thence removal of said transition metal salt complex by means of hydrogen sulfide or ammonium hydroxide.
  • N-protected starting compounds of saturated aminoglycosides having a primary carbinamine at C-5' e.g. 1,3,6',3"-tetra-N-protected gentamicin C 1a
  • Such an N-protected intermediate e.g.
  • 1,3,6',3"-tetra-N-benzyloxycarbonylgentamicin C la is conveniently prepared by first reacting the unblocked aminoglycoside, e.g. gentamicin C la , with about two equivalents of N-(trichloroethoxycarbonyloxy)succinimide in methanol in the presence of excess nickel acetate according to the selective blocking procedure whereby, after decomposition of the nickel acetate complex by means of ammonium hydroxide, there is produced 2',6'-di-N-trichloro- ethoxycarbonylgentamicin C 1a ; secondly, preparing the N-benzyloxycarbonyl derivatives of the remaining amino functions at the 1, 3 and 3"-positions via the well known procedure utilizing benzylchloroformate and calcium hydroxide; thirdly, treating the resulting 1,3,3"-tri-N-benzyloxycarbonyl-2',6'-di-N-(trichlor
  • 1,3,6',3"-tetra-N-ethoxycarbonylgentamicin C 1 is preferably prepared by first reacting gentamicin C 1 with about one equivalent of N-benzyloxy- carbonyloxysuccinimide in the presence of about three equivalents of cupric acetate according to the selective blok- king procedure whereby, after decomposition of the copper complex with ammonium hydroxide, there is obtained 2'-N-benzyloxycarbonylgentamicin C 1 .
  • the N-blocking groups in the unsaturated amino- cyclitol are preferably N-benzoyl blocking groups since such derivatives are less susceptible to glycoside cleavage under the acidic reaction conditions necessary for the deoximation step of this process.
  • a preferred N-blocked sisomicin starting intermediate is 1,3,6'-tri-N-benzoyl-3"-N-acetyl- sisomicin, which is conveniently prepared by first treating sisomicin with excess N-benzoyl imidazole followed by treatment of the resulting 6'-N-benzoylsisomicin with one equivalent of N-(trichloroethoxycarbonyloxy)succinimide in metha- ; nol in the presence of nickel (II) acetate according to the selective blocking procedure whereby (after decomposition of the nickel acetate complex by means of ammonium hydroxide) is produced mainly 2'-trichloroethoxycarbonyl-6'-N-benzoylsisomicin.
  • N-protected starting compounds from aminoglycosides having amino groups at the 2' and 6'-positions and hydroxyl groups at the 3' and 4'-positions (e.g. a 1,3,6'3"-tetra-N-protected-Antibiotic JI-20A)
  • it is preferred to first protect the 6'-position by reacting the aminoglycoside with about one equivalent of N-benzyloxycar- bonyloxyphthalimide in the presence of about one equivalent of cupric chloride according to the selective blocking procedure whereby, after decomposition of the copper complex with ammonium hydroxide there is obtained the 6'-N-benzyloxycarbonyl derivative (e.g.
  • 6'-N-benzyloxycarbonyl-Antibiotic JI-20A The 2'-position is then protected by reaction of the foregoing 6'-N-substituted derivative with about a mole of either N-tert.-butoxycarbonyloxyphthalimide or N-(2,2,2-tri- chloroethoxy)carbonyloxyphthalimide in the presence of about an equivalent of nickel acetate according to the selective blocking method whereby, after decomposition of the nickel complex with ammonium hydroxide, the corresponding 2'-N-tert.-butoxycarbonyl or 2'-N-(2,2,2-trichloroethoxycarbonyl) derivative is formed (e.g.
  • Additional product is obtained by extracting the filtrate with chloroform, drying the chloroform extracts over magnesium sulfate and evaporating the combined extracts in vacuo. Combine both the foregoing residues and purify by passing through silica gel (36 g) eluting with chloroform:methanol (98:2). Evaporate the combined eluates to obtain 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-N-benzyloxycarbonylgentamicin C 1 ; yield 6.89 g.
  • Extract the aqueous mixture with chloroform wash the combined chloroform extracts with aqueous sodium bicarbonate solution, dry the chloroform over sodium sulfate and evaporate to a residue comprising l,3,6',3"-tetra-N-benzyloxycarbonyl-2'-oxo-2'desaminogentamicin C la which is used without further purification in the procedure of following Example lC.
  • Example 2B(1) prepare a solution of N-[S- ⁇ -(benzyloxycarbonylamino)-a-hydroxyvaleryl]succinimide in tetrahydrofuran from S- ⁇ -benzyloxycarbonylamino-a-hydroxyvaleric acid and dry N-hydroxysuccinimide, then add this solution dropwise to a solution of 3',6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C la in aqueous methanol in a manner similar to that described in Example 2B(2).
  • Example 2A In a manner similar to that described in Example 2A, treat 2'-hydroxy-2'-desaminosisomicin in dimethylsulfoxide with cupric acetate and nickelous acetate followed by treatment with N-(benzyloxycarbonyloxy)phthalimide, and then reaction with aqueous ammonium hydroxide. Isolate and purify the resultant product in a manner similar to that described to obtain 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminosisomicin.
  • Example lD In a manner similar to that described in Example lD, treat a solution of each of the compounds prepared in Example 4B in tetrahydrofuran with sodium in liquid ammonia, then isolate and purify each of the resultant products in a manner similar to that described in Example 1D to obtain, respectively, 1-N-(S- ⁇ -amino- ⁇ -hydroxybutyryl]-2'-hydroxy-2'-desaminosisomicin, 1-N-[S-0-amino-a-hydroxypropyl]-2'-hydroxy-2'-desaminosisomicin, and 1-N-[S- ⁇ -amino- ⁇ -hydroxyvaleryl]-2'-hydroxy-2'-desaminosisomicin.
  • Example 6B In a manner similar to that described in Example 6B, treat 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C 1 with each of N-(S- ⁇ -benzyloxycarbonylamino- ⁇ -hydroxybutyryloxy)succinimide and N-(S- ⁇ -benzyloxycarbonylamino- ⁇ -hydroxyvaleryloxy)succinimide and iso- late and purify each of the resultant products in the described manner to obtain 3,6'-di-N-benzyloxycarbonyl-1-N-(S- ⁇ -amino- ⁇ -hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C 1 and 3,6'-di-N-benzyloxycarbonyl-l-N-(S- ⁇ -amino- ⁇ -hydroxyvaleryl)-2'-hydroxy-2'-desaminogentamicin C l , respectively.
  • Example 2A In a manner similar to that described in Example 2A, treat each of the 2'-hydroxy-2'-desamino aminoglycosides prepared in Examples 7A, 7B and 7C with powdered cupric acetate and nickelous acetate followed by treatment with N-(benzyloxycarbonyloxy)phthalimide. Isolate and purify each of the resultant products in a manner similar to that described to obtain the corresponding 3',6'-di-N-benzyloxycarbonyl derivative.
  • Example 2 B (2) In a manner similar to that described in Example 2 B (2), treat each of the 3,6'-di-N-benzyloxycarbonyl- 2'-hydroxy-2'-desamino aminoglycosides prepared in Example 8A with N-(S-Y-benzyloxycarbonylamino-a-hyd- roxybutyryloxy)succinimide, then isolate and purify each of the resultant products in a manner similar to that described to obtain the corresponding 1-N-[S- ⁇ -(benzyloxycarbonylamino)- ⁇ -hydroxybutyryl] derivative.
  • Example 2E In a manner similar to that described in Example 2E, treat each of the 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desamino aminoglycoside derivatives prepared in Examples 7A, 7B and 7C with N-(S- ⁇ -benzyloxycarbonylamino-a-hydroxyvaleryl)succinimide and isolate and purify each of the resultant products in a manner similar to that described to obtain, respectively, the 1-N-[S- ⁇ -(benzyloxycarbonylamino)- ⁇ -hydroxy- valeryl] derivative.
  • hydrochloride salt of the compounds of Examples 2 to 8 are prepared.
  • the 2 1- hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols of this invention exhibit broad spectrum antibacterial activity and possess an improved antibacterial spectrum compared to that of the parent antibiotics.
  • This improved spectrum consists of enhanced potency of the claimed compounds against organisms resistant to the parent compound.
  • 2'-hydroxy-2'-desamino-4-O-aminogly- cosyl-6-0-garosaminyl-2-deoxystreptamines are more active against organisms which inactivate the parent antibiotics by acetylation of the 2'-amino group.
  • the 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and their non-toxic, pharmaceutically acceptable acid addition salts are, in general, less acutely toxic than their precursor 2'-amino parent antibiotics.
  • 2'-hydroxy-2'-desamino-gentamicin C 1 and 2'-hydroxy-2'-desaminogentamicin C 1a which derivatives are broad spectrum antibacterial agents, being active against gram positive bacteria (e.g. Staphylococcus aureus) and gram negative bacteria (e.g. Escherichia coli and Pseudomonas aeruginosa) as determined by standard dilution tests, including,bacteria resistant to the parent compound.
  • Most valuable compounds of this invention are the 1-N-( ⁇ -amino-a-hydroxy) derivatives of 2'-hydroxy-2'-desaminogentamicin Cl a' particularly 1-N-(S- ⁇ -amino- ⁇ -hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C 1a and 1-N-(S- ⁇ -amino- ⁇ -hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C 1a which exhibit broader spectra of antibacterial activity than the precursor 1-N-unsubstituted-2'-hydroxy-2'-desaminogentamicin C la or the corresponding 1-N-(S- ⁇ -amino- ⁇ -hydroxyalkanoyl) gentamicin C la .
  • the 2'-hydroxy-2'-desamino compounds of this invention can be used alone or in combination with other antibiotic agents to prevent the growth or reduce the number of bacteria in various environments. They may be used, for example, to disinfect laboratory glassware, dental and medical equipment contaminated with Staphylococcus aureus or other bacteria inhibited by the 2'-hydroxy-2'-desamino derivatives of this invention.
  • the activity of the 2'-hydroxy-2'-desamino-4,6-di-O-(amino- glycosyl)-l,3-diaminocyclitols against gram negative bacteria renders them useful for combatting infections caused by gram negative organisms, e.g. species of Proteus and Pseudomonas.
  • the 2'-hydroxy-2 1- desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols e.g.
  • the dosage administered of the 2'-hydroxy-2'-desamino-4,6-di-0-(aminoglycosyl)-1,3-diaminocyclitols will be dependent upon the age and wieght of the animal species being treated, the mode of administration, and the type and severity of bacterial infection being prevented or reduced.
  • the dosage employed to combat a given bacterial infection will be similar to the' dosage requirements of the corresponding 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol.
  • the compounds of this invention may be administered orally. They may also be applied topically in the form of ointments, both hydrophilic and hydrophobic, in the form of lotions which may be aqueous, non-aqueous or of the emulsion type or in the form of creams.
  • Pharmaceutical carriers useful in the preparation of such formulations will include, for example, such substances as water, oils, greases, polyesters, polyols and the like.
  • the compounds of this invention may be compounded in the form of tablets, capsules, elixirs or the like or may even be admixed with animal feed. It is in these dosage forms that the antibacterials are most effective for treating bacterial infections of the gastrointestinal tract, which infections cause diarrhea.
  • the topical preparations will contain from about 0.1 to about 3.0 g of a 2'-hydroxy-2'-desamino-4,6-di-O-(amino- glycosyl)-1,3-diaminocyclitol derivative per 100 g of ointment, creams or lotion.
  • the topical preparations are usually applied gently to lesions from about 2 to about 5 times a day.
  • the antibacterials of this invention may be dtilized in liquid form such as solutions, suspensions and the like for otic and optic use and may also be administered parenterally via intramuscular injection.
  • the injectable solution or suspension will usually be administered at from about 1 mg to about 10 mg of antibacterial per kilogram of body weight per day divided into about 2 to about 4 doses. The precise dose depends on the stage and severity of the infection, the susceptibility of the infecting organism to the antibacterial and the individual characteristics of the animal species being treated.
  • Ointments of other 2'-hydroxy-2'-desamino-4,6-di-o-(amino- glycosyl)-1,3-diaminocyclitols of this invention are prepared by substituting an equivalent quantity of 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol or an acid addition salt thereof, for.1-N-(S- ⁇ -amino- ⁇ -hydroxy-butyryl)-2'-hydroxy-2'-desaminogentamicin C 1a in the foregoing example and by following substantially the procedure of the example.
  • injectable solutions of other 2'-hydroxy-2'- desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and especially acid addition salts of such antibacterial agents may be prepared by substituting an equivalent quantity of such compounds for 1-N-(S- ⁇ -amino- ⁇ -hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C 1a sulfate and by following the procedure set forth above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a process for preparing 2'-hydroxy- 2'-desamino-4,6-di-0-(aminoglycosyl) -1,3-diaminocyclitols having a 6'-amino function and pharmaceutically acceptable acid addition salts thereof, to novel compounds and salts obtained by this process; and to novel antibacterially active compositions comprising such novel compounds or salts.
The process comprises reacting the corresponding N-protected (except the 2'-amino)-4,6- di-0- (aminoglycosyl)-1,3-diaminocyclitol with hydrogen peroxide in the presence of tungstate ion, followed by cleavage of the thereby formed 2'-oximino derivative and by reduction of the resulting 2'-oxo derivative and by removal of the N-protecting groups.
The preferred group of novel compounds obtained by this process are the 1-N- (ω-amino-α- hydroxyalkanoyl) -2'-hydroxy-2'- desamino-4,6-di-0- (aminoglycosyl)- 1,3-diaminocyclitols. The compounds obtained by the process of !this invention exhibit antibacterial activity

Description

  • This invention relates to a process for preparing 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols having a 6'-amino function and pharmaceutically acceptable acid addition salts thereof, to novel compounds and salts obtained by this process; and to novel antibacterially active compositions comprising such novel compounds or salts.
  • 4,6-Di-O-(aminoglycosyl)-1,3-diaminocyclitols are generally known in the art. Some of these, e.g. kanamycin A, gentamicin B and gentamicin B1 have a 2'-hydroxy-group and a 6'-amino function. They are, however, obtained microbiologically, e.g. gentamicin B and B1 are coproduced with the gentamicin C complex during the fermentation of certain species of the genus Micromonospora, e.g. M. purpurea as described in U.S. Patents No. 3,091,572 and 3,915,955; and kanamycin is produced microbiologically by the fermentation of certain species of the genus Streptomyces, e.g. S. kanamyceticus as described in U.S. Patent No. 2,931,798.
  • The process of this invention provides a chemical method for preparing novel 2'-hydroxy-2'-desamino-4,6-di-O-(aminogly- cosyl)-1,3-diaminocyclitols having antibacterial activity which cannot be obtained via prior art microbiological methods.
  • In addition the process provides a novel method for preparing known compounds, e.g. gentamicin B (which.is obtained in poor yields, i.e. less than about 10 %, when prepared microbiologically) by converting the known Antibiotic JI-20A into 2'-hydroxy-2'-desamino-Antibiotic JI-20A which has the same structure as gentamicin B.
  • Typical representatives of the novel compounds obtained by the process of this invention are
    • 2'-hydroxy-2'-desaminogentamicin C1,
    • 2'-hydroxy-2'-desaminogentamicin Cla'
    • 2'-hydroxy-2'-desaminogentamicin C2,
    • 2'-hydroxy-2'-desaminogentamicin C2a,
    • 2'-hydroxy-2'-desaminogentamicin C2b,
    • 2'-hydroxy-2'-desaminosisomicin,
    • 2'-hydroxy-2'-desaminoverdamicin,
    • 2'-hydroxy-2'-desamino-Antibiotic G-52,
    • 2'-hydroxy-2'-desamino-Antibiotic 66-40B,
    • 2'-hydroxy-2'-desamino-Antibiotic 66-40D,
    • 2'-hydroxy-2'-desamino-Antibiotic JI-20B,
    • 2'-hydroxy-2'-desaminotobramycin; and
    • 2'-hydroxy-2'-desamino-3',4'-dideoxykanamycin B;
    • the 5-deoxy-, 5-epi-, 5-epi-azido-5-deoxy- and the 5-epi- fluoro-5-deoxy derivatives thereof;
    • 2'-hydroxy-2'-desamino-Antibiotic MU-1, and 2'-hydroxy-2'-desamino-Antibiotic Mu-4;

    and the 1-N-mono-substituted derivatives thereof wherein the substituent R is either an (ω-amino-α-hydroxy-alkanoyl) group having from 3 to 5 carbon atoms or a group CH2X wherein X represents hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, N-alkylaminoalkyl, aminohydroxyalkyl or alkylaminohydroxyalkyl, said aliphatic radicals having up to 7 carbon atoms and, when substituted by both hydroxy and amino, having said substituents attached to different carbon atoms; and the pharmaceutically acceptable acid addition salts thereof.
  • The antibiotics gentamicin C1, C1a' C2' C2a' C2b' sisomicin, verdamicin, Antibiotic G-52, Antibiotic 66-40B, Antibiotic 66-40D, Antibiotic JI-20B, tobramycin, 3',4'-dideoxykanamycin B, Antibiotic Mu-1 and Antibiotic Mu-4, as well as Antibiotic JI-20A (which may be converted into gentamicin B by the process of this invention) may be illustrated by the following formula I
    Figure imgb0001
    whereby, for the various antibiotics listed above, the "substituents" a, b, c, d, f, g, h, i, m, o and p as well as the bond between C4' and C5' are as given in the table be- low.
    Figure imgb0002
  • Included among the substituents contemplated for the grouping CH2X referred to above are straight and branched chain alkyl groups such as ethyl, n-propyl, n-butyl, 0-methylpropyl; cycloalkyl groups such as cyclopropylmethyl; alkenyl groups such as β-propenyl, β-methylpropenyl, β-butenyl; hydroxy substituted straight and branched chain alkyl groups such as β-hydroxy-γ-methylbutyl, β-hydroxy-β-methylpropyl, a-hydroxybutyl, β-hydroxypropyl, γ-hydroxypropyl; amino substituted straight and branched chain alkyl groups such as β-aminopropyl,γ-aminopropyl, a-aminobutyl, and mono-N-alkylated derivatives thereof such as the N-methyl and N-ethyl derivatives, e.g. β-methylaminopropyl; amino and hydroxy disubstituted straight and branched chain alkyl groups such as β-hydroxy-δ-aminobutyl, β-hydroxy-γ-aminopropyl, and β-hydroxy-β-methyl-γ-aminopropyl; and mono-N-alkylated derivatives thereof such as β-hydroxy-γ-ethylaminopropyl.
  • Of the foregoing substituents for the moiety CH2X, preferred are ethyl, n-propyl and δ-aminobutyl.
  • Of the 1-N-substituted derivatives of our invention, preferred are the 1-N-(ω-amino-α-hydroxyalkanoyl)-2'-hydroxy-2'- desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, particularly the 1-N-(γ-amino-α-hydroxybutyryl) and the 1-N-(0-amino-a-hydroxypropionyl) derivatives, particularly valuable compounds being 1-N=(S-γ-amino-a-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin Cla and 1-N-(S-β-amino-α-hydro- xypropionyl)-2'-hydroxy-2'-desaminogentamicin C1a.
  • It is to be noted that the 1-N-(ω-amino-α-hydroxy) substituent.in the foregoing 1-N-(ω-amino-α-hydroxy)-2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols may be in the R,S- form or in the R- form or in the S- form. In accordance with this invention, each of the foregoing names includes all three forms. Thus, the name 1-N-(γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin Cla includes 1-N-(S-γ amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C1a, 1-N-(R-γamino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C1a and 1-N-(R,S-γ-amino-α-hyaroxy- butyryl)-2'-hydroxy-2'-desaminogentamicin C1a.
  • The pharmaceutically acceptable acid addition salts of this invention may be prepared according to known procedures such as by neutralizing the free base with the appropriate acid, usually to about pH 5. Preferred acids for this purpose are hydrochloric, sulfuric, phosphoric and hydrobromic acid. Generally, the acid addition salts are white solids which are soluble in water and insoluble in most polar and nonpolar organic solvents.
  • The process of this invention for the preparation of a 2'- liydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol having an amino function in position 6' is characterised in that the corresponding 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol having an amino function in position 2' wherein all other amino functions are protected by a protecting group, is oxidized by means of hydrogen peroxide in an inert solvent in the presence of tungstate ion at a pH of about 9 to about 11, whereby the molar ratio of hydrogen peroxide to starting compound is at least 2:1, that the so-obtained 2'-oximino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol is subjected to a cleavage of the oxime function; that the so-obtained 2'-oxo-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol is reduced at the oxo group; and that the so-obtained compound is subjected to a removal of the protecting groups.
  • For the oxidation in the first step of the process it is necessary to use at least two moles of hydrogen peroxide per mole of aminoglycoside to ensure completion of reaction. Preferably, a four to five molar excess is used, and in certain instances even greater molar excesses of hydrogen peroxide are advantageously employed.
  • The oxidation is usually carried out at room temperature in aqueous methanol, although other lower alkanols, e.g. ethanol and isopropanol, are conveniently employed. In general, however, any organic solvent which will dissolve the aminoglycoside and which does not react with hydrogen peroxide, e.g. dimethylacetamide, dimethylformamide, tetrahydrofuran, dioxan and diglyme may be used.
  • After addition of the tungstate ion, it is necessary that the pH of the reaction mixture be maintained between 9 and 11 (preferably at pH 10 to pH 10.5), e.g. by addition of a base (sodium hydroxide), in order to minimize side reactions occurring such as glycoside cleavage and protonation of the amine.
  • The reaction is continued until almost all the amino function is consumed as determined by thin layer chromatographic techniques, then the resulting 2'-oximino-N-protected-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol intermediate is isolated as a mixture of syn and anti isomers utilizing known techniques (e.g. extraction and chromatographic techniques).
  • In the second step of the process, the 2'-oximino-N-protected -4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol prepared as described above is cleaved to the corresponding 2'-oxo derivative utilizing known techniques for cleaving oximes. Pre-(ferably, the cleaving of the 2'-oximino function is achieved by an acidic hydrolytic medium in the presence of acetaldehyde (e.g. by treating a solution of the 2'-oximino derivative in acetonitrile with 1N hydrochloric acid containing acetaldehyde) or by reaction of the oximino intermediate with sodium bisulfite followed by mild acid hydrolysis. The latter procedure is preferred since greater yields of purer product are usually obtained thereby. When carrying out this procedure, the 2'-oximino-N-protected aminoglycoside intermediate in aqueous ethanol (or other aqueous lower alkanol) is usually reacted with about three to four molar equivalents of sodium bisulfite at reflux temperature until the oximino function is consumed as determined by thin layer chromatographic techniques. There is then added a weak acid (e.g. acetic acid or oxalic or tartaric acid) to produce a mild acid hydrolytic medium; the reaction mixture is then heated at reflux temperature until the reaction is complete as evidenced by thin layer chromatographic techniques.
  • Reduction of the 2'-oxo-N-protected aminoglycoside intermediate in the third step is preferentially carried out by reaction with an alkali metal borohydride (usually sodium borohydride) according to known procedures for reducing a keto group to a hydroxyl function, and there is obtained an excellent yield of N-protected-2'-hydroxy-2'-desamino-aminoglycoside in which the 2'-hydroxyl function is in the equatorial position, i.e. the same stereoconfiguration as the starting 2'-amino function. After removal of the N-protecting functions according to known techniques, the resulting 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol is isolated and purified utilizing conventional techniques.
  • When carrying out the process, all the functions desired in the final 2'-hydroxy-2'-desanino derivative may be present in the 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol precursor. Thus, for example, when preparing 1-N-ethyl-2'-hydroxy= 2'-desaminosisomicin, or 5-deoxy-2'-hydroxy-2'-desaminosisomicin, the corresponding 1-N-ethylsisomicin or 5-deoxysisomicin may be used as starting compounds. Alternatively, the 2'-amino function in a 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol can be replaced by a hydroxyl group via the process of this invention, then other functions may be introduced into the 2'-hydroxy-2'-desamino-aminoglycoside by methods known in the art. This alternate method is the method of choice when preparing the preferred 1-N-(ω-amino-α-hydroxyalkanoyl)-2'-hydroxy-2'-desamino derivatives of this invention. Thus, for example, when preparing 1-N-(S-β-amino-α-hydroxy-propionyl)-2'-hydroxy-2'-desaminogentamicin C1a and 1-N-(γ-amino-a-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin Cla, a preferred method involves first converting gentamicin C1a to 2'-hydroxy-2'-desaminogentamicin C1a via the process of this invention, and thence converting 2'-hydroxy-2'-desaminogentamicin C1a to the 1-N-(S-β-amino-α-hydroxypropionyl)- or the 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin Cla utilizing techniques known in the art and as described in the examples.
  • Typical starting compounds are the 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol antibacterial agents described by formula I in combination with Table I above. Particularly useful starting antibiotic precursors are sisomicin and gentamicin C1a which lead to preferred 2'-hydroxy-2'-amino derivatives of this invention, and Antibiotic JI-20A which leads to gentamicin B.
  • Other useful starting antibiotic precursors include 5-epi-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol antibacterials described in U.S. Patent No. 4,000,261; 5-epi-azido-5-deoxy-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol antibacterials described in U.S. Patent No. 4,000,262; l-N-alkyl-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol antibacterials described in U.S. Patent No. 4,002,742; 5-deoxy-4,6-di-O-(amino- glycosyl)-1,3-diaminocyclitol antibacterials described in U.S. Patent No. 4,053,591; and 5-epi-fluoro-5-deoxy-4,6-di-0-(aminoglycosyl)-1,3-diaminocyclitol antibacterials described in South African Patent No. 78/0385.
  • A 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol of this invention may be converted to a corresponding 1-N-alkyl derivative or to a corresponding 5-deoxy-, or a 5-epi- or 5-epi-azido-5-deoxy derivative, via procedures analogous to those described in the above-mentioned patents.
  • Thus, for example, a 2'-hydroxy-2'-desamino-4,6-di-O-(amino- glycosyl)-2-deoxystreptamine of this invention (e.g. 2'-hydroxy-2'-desaminosisomicin) is converted to the corresponding 5-deoxy derivative (e.g. 2'-hydroxy-2'-desamino-5-deoxysisomicin) by first converting said 2'-hydroxy-2'- desamino-4,6-di-O-(aminoglycosyl)-2-deoxystreptamine to the corresponding N- and 0-protected (except for the 5-hydroxyl group) intermediate (e.g. 1,3,6'-tri-N-benzyloxycarbonyl-2',2"-di-O-benzoyl-3",4"-N,O-carbonyl-2'-hydrbxy-2'-desaminosisomicin) utilizing known techniques, then converting the 5-hydroxyl group to the 5-0-thioformate ester by reaction with the Vilsmaier salt produced from phosgene and N,N-dimethylformamide in dichloromethane, followed by reaction of the imidinium chloride salt thereby produced (e.g. 1,3,6'-tri-N-benzyloxycarbonyl-2',2"-di-O-benzoyl-3",4"-N,O-carbonyl-2'-hydroxy-2'-desaminosisomicin-5-O(N,N-dimethylformimidi- nium)chloride) with hydrogen sulfide in pyridine, thence reaction of the requisite 5-0-thioformyl ester thereby formed (e.g. 1,3,6'-tri-N-benzyloxycarbonyl-5-O-thioformyl-2',2"- di-O-benzoyl-3",4"-N,O-carbonyl-2'-hydroxy-2'-desaminosisomicin) with tri-n-butylstannane in toluene and, finally, removal of the N- and 0-protecting groups in the resulting 5-deoxy derivative via known procedures to obtain a 5-deoxy-2'-desamino-2'-hydroxy compound of this invention (e.g. 2'-hydrQxy-2'-desamino-5-deoxysisomicin).
  • Similarly, a 2'-hydroxy-2'-dQSamino-4,6-di-O-(aminoglycosyl)-2-deoxystreptamine of this invention is converted to the corresponding 5-epi-fluoro-5-deoxy derivative according to procedures analogous to those described in South African Patent No. 78/0385, whereby an N- and O-protected-2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-2-deoxystreptamine having a free 5-hydroxyl group (e.g. 1,3,6'-tri-N-benzyloxycarbonyl-2',2"-di-Obenzoyl-3",4"-N,0-carbonyl-2'-hydroxy-2'-desaminosisomicin) is reacted with a dialkylaminosulfur trifluoride, preferably diethylaminosulfur trifluoride in methylene chloride, followed by treatment with sodium bicarbonate and then removal of the N- and 0-protecting groups to obtain a 5-epi-fluoro-2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-2,5-dideoxystreptamine of this invention (e.g. 5-epi-fluoro-2'-hydroxy-2'-desamino-5-deoxysisomicin).
  • The N-protected starting compounds of our process, wherein all amino functions except the 2'-amino group in a 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol are protected by groups susceptible to reductive cleavage or basic hydrolysis, are conveniently prepared by combining procedures known in the art, together with a selective blocking procedure described in Belgian Patent No. 855704. By the selective blocking procedure, a transition metal salt complex between available neighboring amino and hydroxyl functions in said 4,6-di-O-(aminoglycosyl)-1,3-diamtnocyclitol and cupric acetate or nickel (II) acetate is first prepared followed by introduction of acyl functions on non-complexed and/or weakly complexed amino functions, and thence removal of said transition metal salt complex by means of hydrogen sulfide or ammonium hydroxide.
  • When preparing N-protected starting compounds of saturated aminoglycosides having a primary carbinamine at C-5', e.g. 1,3,6',3"-tetra-N-protected gentamicin C1a, it is usually preferred to block the amino functions by hydrocarbonyloxy- carbonyl groups which are susceptible to reductive cleavage (e.g. with sodium in ammonia) or to alkaline hydrolysis, e.g. by utilizing blocking groups such as benzyloxycarbonyl, ethoxycarbonyl, and methoxycarbonyl groups, Such an N-protected intermediate, e.g. 1,3,6',3"-tetra-N-benzyloxycarbonylgentamicin Cla, is conveniently prepared by first reacting the unblocked aminoglycoside, e.g. gentamicin Cla, with about two equivalents of N-(trichloroethoxycarbonyloxy)succinimide in methanol in the presence of excess nickel acetate according to the selective blocking procedure whereby, after decomposition of the nickel acetate complex by means of ammonium hydroxide, there is produced 2',6'-di-N-trichloro- ethoxycarbonylgentamicin C1a; secondly, preparing the N-benzyloxycarbonyl derivatives of the remaining amino functions at the 1, 3 and 3"-positions via the well known procedure utilizing benzylchloroformate and calcium hydroxide; thirdly, treating the resulting 1,3,3"-tri-N-benzyloxycarbonyl-2',6'-di-N-(trichloroethoxycarbonyl)-gentamicin C1a with zinc in acetic acid whereby are removed the trichloro- ethoxycarbdnyl groups to produce 1,3,3"-tri-N-benzyloxy- carbonylgentamiciw C1a; then, finally, blocking the more reactive 5'-primary carbinamine group by reaction of the 1,3,3"-tri-N-blocked derivative with about one equivalent of N-(benzyloxycarbonyloxy)phthalimide in the presence of excess triethylamine to produce the desired 1,3,6',3"-tetra-N-benzyloxycarbonylgentamicin C1a, a requisite intermediate of the process of this invention.
  • When preparing N-blocked aminoglycoside staring compounds from saturated 4,6-di-O-(aminoglycosyl)-1,3-diaminocycli- tols having a secondary amino function at the 6'-position (such as in gentamicin Cl), the requisite 1,3,6',3"-tetra-N-blocked intermediate (e.g. 1,3,6',3"-tetra-N-ethoxycarbonylgentamicin C1) is preferably prepared by first reacting gentamicin C1 with about one equivalent of N-benzyloxy- carbonyloxysuccinimide in the presence of about three equivalents of cupric acetate according to the selective blok- king procedure whereby, after decomposition of the copper complex with ammonium hydroxide, there is obtained 2'-N-benzyloxycarbonylgentamicin C1. Reaction of the foregoing derivative with over four equivalents of ethoxycarbonyl chloride and sodium carbonate, followed by removal of the 2'-benzyloxycarbonyl group via reductive cleavage by means of hydrogen in the presence of palladium-on-charcoal catalyst yields 1,3,6',3"-tetra-N-ethoxycarbonyl-gentamicin Cl.
  • When preparing 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglyco- syl)-1,3-diaminocyclitols having double bonds, such as in sisomicin, the N-blocking groups in the unsaturated amino- cyclitol are preferably N-benzoyl blocking groups since such derivatives are less susceptible to glycoside cleavage under the acidic reaction conditions necessary for the deoximation step of this process. Thus, a preferred N-blocked sisomicin starting intermediate is 1,3,6'-tri-N-benzoyl-3"-N-acetyl- sisomicin, which is conveniently prepared by first treating sisomicin with excess N-benzoyl imidazole followed by treatment of the resulting 6'-N-benzoylsisomicin with one equivalent of N-(trichloroethoxycarbonyloxy)succinimide in metha- ; nol in the presence of nickel (II) acetate according to the selective blocking procedure whereby (after decomposition of the nickel acetate complex by means of ammonium hydroxide) is produced mainly 2'-trichloroethoxycarbonyl-6'-N-benzoylsisomicin. Treatment of the foregoing with excess benzoic anhydride in methanol yields 1,3,6'-tri-N-benzoyl-2'-(tri- chloroethoxycarbonyloxy)sisomicin which, upon reaction with excess acetic anhydride followed by treatment with zinc in acetic acid in methanol yields 1,3,6'-tri-N-benzoyl-3"-N-acetylsisomicin.
  • When preparing N-protected starting compounds from aminoglycosides having amino groups at the 2' and 6'-positions and hydroxyl groups at the 3' and 4'-positions (e.g. a 1,3,6'3"-tetra-N-protected-Antibiotic JI-20A), it is preferred to first protect the 6'-position by reacting the aminoglycoside with about one equivalent of N-benzyloxycar- bonyloxyphthalimide in the presence of about one equivalent of cupric chloride according to the selective blocking procedure whereby, after decomposition of the copper complex with ammonium hydroxide there is obtained the 6'-N-benzyloxycarbonyl derivative (e.g. 6'-N-benzyloxycarbonyl-Antibiotic JI-20A). The 2'-position is then protected by reaction of the foregoing 6'-N-substituted derivative with about a mole of either N-tert.-butoxycarbonyloxyphthalimide or N-(2,2,2-tri- chloroethoxy)carbonyloxyphthalimide in the presence of about an equivalent of nickel acetate according to the selective blocking method whereby, after decomposition of the nickel complex with ammonium hydroxide, the corresponding 2'-N-tert.-butoxycarbonyl or 2'-N-(2,2,2-trichloroethoxycarbonyl) derivative is formed (e.g. 2'-N-tert.-butoxycarbonyl- or 2'-N-(2,2,2-trichloroethoxycarbonyl)-6'-N-benzyloxycarboyl-Antibiotic JI-20A).. Reaction of the foregoing 2',6'-di-N-protected-aminoglycoside with over three equivalents of benzyloxy- carbonylchloride according to standard blocking procedures, followed by removal fo the 2'-N-tert.-butoxycarbonyl-protecting group with trifluoroacetic acid or removal of the 2'-N-(2,2,2-trichloroethoxy)-protecting group by treatment with trifluoroacetic acid or zinc and acetic acid in methanol respectively yields a 1,3,6',3"-tetra-N-protected-Aminoglycoside starting compound of this invention, e.g. l,3,6',3"-tetra-N-benzyloxy-Antibiotic JI-20A.
  • It will be obvious to one skilled in the art that other requisite 1,3,6',3"-tetra-N-acyl aminoglycoside starting compounds of this process can be prepared by other combinations of acylating procedures known in the art together with the selective blocking procedures disclosed in Belgian Patent No. 855704.
  • PREPARATION I 1,3,6',3"-TETRA-N-BENZYLOXYCARBONYLGENTAMICIN C1a A. 2',6'-Di-N-(2,2,2-Trichloroethoxycarbonyl)Gentamicin C1a
  • To a solution of gentamicin Cla (5.0 g) and nickel (II) acetate (10.0 g) in methanol (250 ml) at O°C with stirring add N-(2,2,2-trichloroethoxycarbonyloxy)succinimide (6.25 g). Allow the solution to reach room temperature and stir at room temperature for an hour, then evaporate in vacuo until the reaction solution has a volume of about 100 ml. Add 2 N ammonium hydroxide (500 ml), extract with chloroform (three 120 ml portions), dry the combined extracts with potassium carbonate and evaporate. Purify the resultant residue by chromatography on silica gel (300 g) eluting with a chloroform:methanol:concentrated ammonium hydroxide (4:1:0.1) solvent system. Combine the like eluates of desired product as determined by thin layer chromatography and evaporate. Dissolve the resultant residue in chloroform (30 ml), add the chloroform solution to a stirred mixture of hexane (400 ml) and ether (100 ml). Separate the resultant precipitate by filtration and dry at 60°C in vacuo (1 mm) to obtain 2',6'-di-N-(2,2,2-trichloroethoxycarbonyl)-gentamicin Cla; yield 4.9 g; 62 % theory; m.p. 119-122°C;
    Figure imgb0003
    + 95.4 (chloroform, c=0.48).
  • B. 1,3,3"-Tri-N-Benzyloxycarbonylgentamicin Cla
  • a To a solution of 2,6'-di-N-(2,2,2-trichloroethoxycarbonyl)gentamicin Cla (17.0 g) and calcium hydroxide (25 g) in methanol (250 ml) cooled to 5°C, add over a 2-minute interval benzoyl chloroformate (25 ml). Allow the solution to reach room temperature and stir at room temperature for 30 minutes. Dilute the reaction mixture (now containing 1,3,3"-tri-N-benzyloxycarbonyl-2',6-di-N-(2,2,2-trichloroethoxycarbonyl)gentamicin Cla) with methanol (250 ml), water (100 ml) and acetic acid (75 ml). Add zinc dust (40 g) and stir at room temperature for 30 minutes, then stir and heat at reflux temperature for one hour. Cool, remove the zinc by filtration and wash with methanol (two portions of 25 ml). Add the combined filtrate and washings to a mixture of ice (1000 g) and concentrated ammonium hydroxide (500 ml). Extract the aqueous mixture with chloroform (800 ml), then two 300 ml portions. Wash the combined extracts with water and evaporate. Chromatograph the resultant residue on silica gel (350 g) eluting with a solvent mixture of chloroform:Methanol:concentrated ammonium hydroxide ' (10:1:0.1). Evaporate the combined, like eluates as determined by thin layer chromatography, dissolve the resultant residue in chloroform (50 ml), and add the chloroform solution dropwise to a stirred mixture of ether (100 ml) and hexane (700 ml). Separate the resultant precipitate by filtration and dry in vacuo at 60°C to give 1,3,3"-tri-N-benzyloxycarbonylgentamicin C1a; yield 11.7 g; 65 % theory; m.p. 110-113°C;
    Figure imgb0004
    96.5° (chloroform, c=0.55).
  • C. 1,3,6',3"-Tetra-N-Benzyloxycarbonylgentamicin Cla
  • To a stirred solution of l,3,3"-tri-N-benzyloxycarbonylgentamicin Cla (9.35 g) and triethylamine (6.0 ml) in chloroform (100 ml) at 0 - 5°C, add dropwise over a 5-minute period a solution of N-(benzyloxycarbonyloxy) phthalimide (3.2 g) in chloroform (90 ml). Stir the reaction mixture an additional 10 minutes, then wash the reaction mixture with ammonium hydroxide (2 Normal). Dry over potassium carbonate and evaporate. Chromatograph the resultant residue on silica gel (200 g) eluting with a solvent mixture comprising chloroform:methanol:concentrated ammonium hydroxide (20:1:0.1). Combine the like eulates containing the desired product as determined by thin layer chromatography and evaporate. Dissolve the resultant residue in a minimum quantity of chloroform and add the chloroform dropwise to hexane (500 ml). Separate the resultant precipitate by filtration, dry in vacuo at 60°C to give 1,3,6',3"-tetra-N-benzyloxycarbonylgentamicin Cl ; yield 8.5 g (79 % theory); m.p. 101 - 104°C;
    Figure imgb0005
    + 73.9° (chloroform, c=0.48).
  • PREPARATION 2 3"-N-ACETYL-1,3,6'-TRI-N-BENZOYLSISIMICIN A. 6'-N-Benzoylsisomicin
  • To a solution of sisomicin (10 g) in methanol (100 ml) at 0 - 5°C, add dropwise a solution of N-benzoyl imidazole (7 g, 2 equivalents) in chloroform (30 ml). Stir the reaction mixture at room temperature for 30 minutes, concentrate in vacuo to a small volume, dissolve the resultant syrupy residue in choroform (70 ml) and add the chloroform solution slowly to stirred ether (650 ml). Separate the resultant precipitate by filtration, wash with ether and dry in vacuo at 50°C to obtain 6'-N-benzoylsisomicin (14 g) which is used without further purification in the. procedure of Preparation 2B.
  • B. 2'-N-(2,2,2-Trichloroethoxycarbonyl)-6'-N-Benzoylsisomicin
  • Dissolve 6'-N-benzoylsisomicin (14 g) in methanol (450 ml) and add nickel (II) acetate (25 g) and stir for 20 minutes at room temperature. Cool the reaction mixture to 0 - 5°C, and add dropwise a solution of N-(2,2,2-trichloroethoxycarbonyloxy)succinimide (6.4 g, 1.1 equivalents) in chloroform (40 ml). Stir at room temperature for 30 minutes, then add concentrated ammonium hydroxide (25 ml) and evaporate in vacuo to a volume of about 100 ml. Dilute the resultant residue with 3 N ammonium hydroxide (250 ml) and extract with chloroform (two 200 ml portions). Dry the combined extracts over potassium carbonate, filter and evaporate in vacuo to a residue comprising 2'-N-(2,2,2-trichloroethoxycarbonyl-6'-N-benzoylsisomicin, which is used without further purification in the procedure of Preparation 2C.
  • C. 1,-3,6'-Tri-N-BeAzoyl-2,"-N- (2,2,2-trichloroethoxycarbonyl)-Sisomicin
  • Prepare a solution of 2'-N-(2,2,2-trichloroethoxycarbonyl)-6'-N-benzoylsisomicin product of Preparation 2B in methanol (120 ml), and chloroform (60 ml), then with stirring add anhydrous sodium carbonate (20 g) followed by a dropwise addition of benzoic anhydride (12.1 g) in chloroform (40 ml). Stir the reaction mixture at room temperature for one hour, add chloroform (300 ml) and wash the organic solution with water (150 ml). Evaporate the organic phase in vacuo to a volume of about 100 ml, then to the resulting suspension add ether (500 ml) with agitation. Separate the resultant precipitate by filtration and wash with ether to obtain l,3,6'-tri-N-benzoyl-2'-N-(2,2,2-trichloroethoxycarbonyl) sisomicin, which is used without further purification in the procedure of Preparation 2D.
  • D. 1,3,6'-Tri-N-Benzoylsisomicin
  • To a solution of 1,3,6'-tri-N-benzoyl-2'-N-(2,2,2-trichloroethoxycarbonyl)sisomicin product of Preparation 2C in methanol (250 ml) and acetic acid (30 ml), add with stirring zinc dust (30 g) and stir for 30 minutes at room temperature and at reflux temperature for 1 1/2 hours. Decant the reaction solution (from any undissolved zinc which may remain) into 2 N ammonium hydroxide (1.2 liters) and extract the aqueous mixture with chloroform (three 500 ml portions). Dry the combined extracts over potassium carbonate, filter and evaporate in vacuo. Dissolve the resultant residue in hot methanol (50 ml), add warm ethyl acetate (250 ml) and stir the mixture gently for 18 hours at room temperature. Separate the resultant-precipitate by filtration, wash with ethyl acetate and dry in vacuo at 60°C to obtain 1,3,6'-tri-N-benzoylsisomicin; yield 7.0 g; m.p. 233 - 236o C; [α]26 D + 97.40 (aqueous tetrahydrofuran, c=0.50).
  • E. 1,3,6'-Tri--N-Benzoyl-3"-N-Acetylsisomicin
  • To a solution of 1,3,6'-tri-N-benzoylsisomicin (16.o g) in tetrahydrofuran (300 ml) and water (200 ml) add with stirring over a 15-minute interval a solution of N-(2,2,2-trichloroethoxycarbonyloxy)succinimide (6.1 g) in tetrahydrofuran (70 ml). Stir the reaction mixture for 15 minutes, then add acetic anhydride (20 ml) and continue stirring the reaction mixture for one hour at room temperature. Add 500 ml of chloroform, then with stirring add sodium carbonate (30 g). Separate the organic and aqueous phases, evaporate the organic phase in vacuo, dissolve the resultant residue in methanol (165 ml) and acetic acid (15 ml). Add zinc dust (20 g), stir for 30 minutes, then add additional acetic acid (5 ml). Stir the reaction mixture at reflux temperature for 1 hour, then cool and decant from any excess zinc into a mixture of ice (400 g) and concentrated ammonium hydroxide (200 ml). Extract the mixture with chloroform (three portions of 300 ml). Dry the combined extracts over potassium carbonate and evaporate in vacuo. Chromatograph the resultant residue on silica gel (about 300 g) eluting with a solvent mixture comprising chloroform: methanol:concentrated ammonium hydroxide (10:1:0.1). Evaporate the combined, like fractions containing the desired product as determined by thin layer chromatography, dissolve the resultant residue in chloroform (50 ml) and methanol (5 ml) and add to a stirred mixture of ether (700 ml) and hexane (350 ml). Collect the resultant precipitate by filtration, wash with ether, and dry in vacuo at 60°C to obtain 1,3,6'-tri-N-benzoyl-3"-N-acetylsisomicin; yield 9.3 g; m.p. ca. 220°C (decomp.);
    Figure imgb0006
    + 121° (dimethylformamide, c=0.40).
  • PREPARATION 3 1,3,6',3"-TETRA-N-ETHPXYCARBONYLGENTAMICIN C1 A. 2'-N-benzyloxycarbonylgentamicin C1
  • To a stirred solution of gentamicin C1 (30 g) in dimethylsulfoxide (5.4 liters) add cupric acetate monohydrate (37.2 g). Stir until solution occurs, then add N-benzyl- oxycarbonyloxysuccinimide (22.2 g) in tetrahydrofuran (100 ml). Stir the reaction mixture for 30 minutes, pour into water (3 liters) extract continuously with chloroform and discard the chloroform extracts. To the aqueous solution add acetyl acetone (20 ml), stir vigorously at room temperature for 3 hours, then filter. Pass the filtrate through IRA-401S (OH) resin (300 mg), then freeze-dry and chromatograph the resultant residue over silica gel (500 g) eluting with a solvent mixture comprising chloroform:methanol:15 % ammonium hydroxide (2:1:1). Evaporate the combined, like eluates containing the desired product as determined by thin layer chromatography to a residue of 2'-N-benzyloxycarbonylgentamicin Cl; yield 7.3 g.
  • B. 1,3,6',3"-Tetra-N-Ethoxycarbonyl-2'-N-Benzyloxycarbonylgentamicin C 1
  • To a solution of 2'-N-benzyloxycarbonylgentamicin C1 (5.7 g) and sodium carbonate (19.6 g) in methanol (200 ml) and water (200 ml) at 0 - 4°C, add with stirring ethoxycarbonyl chloride (6.72 ml) and vigorously stir the reaction mixture for 24 hours at 0 - 4oC. Separate the resultant precipitate by filtration, wash with water (two portions of 100 ml), dry in vacuo at 450C to a residue comprising 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-benzyloxycarbonylgentamicin C1. Additional product is obtained by extracting the filtrate with chloroform, drying the chloroform extracts over magnesium sulfate and evaporating the combined extracts in vacuo. Combine both the foregoing residues and purify by passing through silica gel (36 g) eluting with chloroform:methanol (98:2). Evaporate the combined eluates to obtain 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-N-benzyloxycarbonylgentamicin C1; yield 6.89 g.
  • C. 1,3,6',3"-Tetra-N-Ethoxycarbonylgentamicin C1
  • Dissolve the 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-N-benzyloxycarbonylgentamicin C1 (6.89 g) product of Preparation 3 B in ethanol (200 ml) and hydrogenate utilizing 30 % palladium-on-charcoal catalyst (30 %, 0.5 g). Filter the reaction mixture, evaporate the filtrate and chromatograph the resultant residue over silica gel (25 g) eluting with chloroformmethanol (95:5). Evaporate the combined, like eluates to a residue comprising 1,3,6',3"-tetra-N-ethoxycarbonylgentamicin Cl, yield 5.1 g.
  • PREPARATION 4 1,3,6',3"-TETRA-N-ETHOXYCARBONYLGENTAMICIN C2b
  • Subject gentamicin C2b to the series of reactions described in Preparations 3A, 3B and 3C to obtain 1,3,6',3"-tetra-N-ethoxycarbonylgentamicin C2b.
  • PREPARATION 5 1,3,6'-TRI-N-BENZOYL-3"-N-ACETYL-4'(5')-DEHYDRO AMINOGLYCOSIDES
  • Subject each of the following aminoglycosides to the series of reactions described in Preparation 2(A)-(E): Antibiotic G-52, Antibiotic 66-40D, Antibiotic 66-40B, verdamicin, Antibiotic Mu-1, 5-deoxysisomicin, Antibiotic Mu-4, 5-epi- sisomicin, 5-epi-azido-5-deoxysisomicin, and 1-N-ethylsisomicin. Isolate and purify each of the resultant products in a manner similar to that described in Preparation 2E to obtain the 1,3,6'-tri-N-benzoyl-3"-N-acetyl derivative of each of the aforenamed starting aminoglycosides.
  • PREPARATION 6 1,3,6',3"-TETRA-N-BENZYLOXYCARBONYL DERIVATIVES OF TOBRAMYCIN, GENTAMICIN C2, AND GENTAMICIN C2a A. 1,3,6',3"-Tetra-N-benzyloxycarbonyltobramycin, Gentamicin C2, and Gentamicin C2a
  • Subject each of tobramycin, gentamicin C2, gentamicin C2a and 3',4'-dideoxykanamycin B to the series of reactions described in Preparations lA, 1B, lC and isolate each of the resultant products in a manner similar to that described to obtain, respectively, 1,3,6',3"-tetra-N-benzyloxycarbonyltobramycin, l,3,6',3"-tetra-N-benzyloxycarbonylgentamicin C2' 1,3,6',3"-tetra-N-benzyloxycarbonylgentamicin C2a and 1,3,6',3"-tetra-N-benzyloxycarbonyl-3',4'-dideoxykanamycin B.
  • PREPARATION 7 1,3,6',3"-TETRA-N-BENZYLOXYCARBONYL DERIVATIVES OF ANTIBIOTICS JI-20A AND JI-20B A. 6'-N-Benzyloxycarbonyl-Antibiotic JI-20A
  • To a solution of Antibiotic JI-20A (1.44 g) in water (1.5 ml), dimethylsulfoxide (58.5 ml) and triethylamine (0.6 ml) add cupric chloride (0.51 g). Stir for 15 minutes at room temperature, then add N-benzyloxycarbonyloxy- phthalimide (0.910 g) and dissolve in dimethylsulfoxide (5 ml). After 1 hour add additional N-benzyloxycarbonyl- oxyphthalimide (0.6 g) in dimethylsulfoxide (4 ml) and stir. Pour the reaction mixture into ether, decant, add ether and stir, then decant again and repeat this procedure several times; Dissolve the resulting syrupy residue in 200 ml of methanol, bubble hydrogen sulfide through the methanol solution, separate the resulting copper sulfide salt precipitate by filtration, stir the filtrate with IRA-401S (OH⊖) resin (50 ml) and separate the resin by filtration. Evaporate the filtrate and chromatograph the resultant residue on silica gel (100 g) eluting with chloroform:methanol:28 % ammonium hydroxide (2:1:0.35). Combine the like fractions containing the desired product as determined by thin layer chromatography and evaporate to a residue comprising 6'-N-benzyloxycarbonyl-Antibiotic JI-20A.
  • B. 2'-N-Tert.-Butoxycarbonyl-6'-N-Benzyloxycarbonl-Antibiotic JI-20A
  • Dissolve 6'-N-benzyloxycarbonyl-Antibiotic JI-20A (0.517 g) in methanol (15 ml), then add nickel (II) acetate tetrahydrate (0.21 g) and stir at room temperature for 15 minutes. Add-N-tert.-butoxycarbonyloxyphthalimide (0.22 g) and stir for 3 hours while adding every hour additional portions of N-tert.-butoxycarbonyloxyphthali- mide (0.2 g each). Bubble hydrogen sulfide through the reaction mixture, separate the resultant nickel salts by filtration, stir the filtrate with IRA-401S (OH⊖) resin (20 ml) and separate the resin by filtration. Evaporate the filtrate and chromatograph the resultant syrupy residue on 50 g of silica gel eluting with chloroform: methanol:28 % ammonium hydroxide (30:10:1). Combine the like fractions containing the desired product as determined by thin layer chromatography and evaporate to a residue comprising 2'-N-tert.-butoxycarbonyl-6'-N-benzyloxycarbonyl-Antibiotic JI-20A.
  • C. 1,3,6',3"-Tetra-N-Benzyloxycarbonyl-2'-N-Tert.-Butoxycarbonyl-Antibiotic JI-20A
  • Dissolve 2'-N-tert.-butoxycarbonyl-6'-N-benzyloxycarbonyl-AntibioticJI-20A (0.716 g) in methanol (15 ml) and stir (5 ml). Cool the solution to 0°C, add sodium carbonate (0.53 g) and then add benzyloxycarbonyl chloride (0.74 ml). Allow the reaction(mixture to stand for 3 hours, then pour into 50 ml of water. Separate the resultant precipitate by filtration, wash the precipitate with water and then ether, then dry in vacuo to obtain 1,3,6',3"-tetra-N-benzyloxycarbonyl-21-N-tert.-butoxycarbonyl-Antibiotic JI-20A.
  • D. Dissolve l,3,6',3"-tetra-N-benzyloxycarbonyl-2'-N-tert.-. butoxycarbonyl-Antibiotic JI-20A (1.121 g) in trifluoroacetic acid (5 ml). Allow the reaction mixture to stand at room temperature for 3 minutes, then add 50 ml of ether and separate the resultant precipitate by filtration. Dissolve the precipitate in methanol (30 ml) and stir with IRA-101S (OH⊖) ion exchange resin (10 ml). Separate the resin by filtration, add ether to the filtrate and separate the resultant precipitate by filtration to obtain 1,3,6',3"-tetra-N-benzyloxycarbonyl-Antibiotic JI-20A.
  • E. 1,3,6',3"-Tetra-N-Benzyloxycarbonyl-Antibiotic JI-20B
  • Treat Antibiotic JI-20B in a manner similar to that described in above Preparations 7A, 7B, 7C and 7D to obtain l,3,6',3"-tetra-N-benzyloxycarbonyl-Antibiotic JI-20B.
  • EXAMPLE 1 2'-HYDROXY-2'-DESAMINOGENTAMICIN C1a (3',4'-DIDEOXYGENTA-MICIN B) A. 1,3,6',3"-Tetra-N-Benzyloxycarbonyl-2'-Oximino-2'-Des- amino-Gentamicin C1a
  • Stir a solution of 1,3,6',3"-tetra-N-benzyloxycarbonylgentamicin Cla (7.0 g) in methanol (80 ml) with aqueous hydrogen perioxide (30 %, 5 g), then add a solution of sodium tungstate (0.3 g) in water (2 ml). Stir the reaction mixture at 15-20°C keeping the solution at a pH of about 10-10.5 by periodic small additions of 1 N sodium hydroxide. Monitor the progress of the reaction via thin layer chromatography for almost complete consumption of the 2'-amino function (4-5 hours). Add the reaction mixture to water (700 ml) containing concentrated hydrochloric acid (2 ml). Extract the aqueous mixture with chloroform (two portions of 250 ml), wash the combined extracts with water, dry over magnesium sulfate and evaporate. Purify the resultant residue via rapid chromatography on silica gel (200 g) eluting with 4 % chloroform in methanol. Combine the like eluates containing the mixture of syn and anti of the desired 2'- oximino product and evaporate in vacuo at 60°C to obtain an isomeric mixture of syn and anti 1,3,6',3"- tetray-N-benzyloxycarbonyl-2'-oximino-2'-desaminogentamicin Cla; yield 5.70 g; 80 % theory, which is used without further purification in the procedure of following Example 1B.
  • B. 1,3,6',3"-Tetra-N-Benzyloxycarbonyl-2'-Oxo-2'-DesaminoGentamicin C1a
  • Stir at reflux temperature a solution of 1,3,6',3"-tetra-N-benzyloxycarbonyl-2'-oximino-2'-desaminogentamicin C1a (isomeric mixture prepared as described in Example lA) and sodium bisulfite (5.5 g) in ethanol (65 ml) and water (28 ml). After stirring for 10 minutes, add additional sodium bisulfite (2.5 g) and continue stirring at reflux temperature for 45 minutes. Add acetic acid (15 ml), stir the reaction mixture at reflux temperature an additional 45 minutes, then pour into water (500 ml). Extract the aqueous mixture with chloroform, wash the combined chloroform extracts with aqueous sodium bicarbonate solution, dry the chloroform over sodium sulfate and evaporate to a residue comprising l,3,6',3"-tetra-N-benzyloxycarbonyl-2'-oxo-2'desaminogentamicin Cla which is used without further purification in the procedure of following Example lC.
  • C. 1,3,6',3"-Tetra-N-Benzyloxycarbonyl-2'-Hydroxy-2'-Des- amino-Gentamicin C la
  • Dissolve the 1,3,6',3"-tetra-N-benzyloxycarbonyl-2'-oxo-2'-desaminogentamicin Cla prepared in Example 1B in tetrahydrofuran (35 ml) and ethanol (35 ml), and with stirring add a solution of sodium borohydride (1 g) in water (5 ml). Stir the reaction mixture at room temperature for 10 minutes, then carefully add acetic acid until the solution is at a pH of about 10. Pour the reaction mixture into a large volume of water and extract with chloroform. Wash the combined chloroform extracts with water, dry over magnesium sulfate and evaporate in vacuo and dry the resultant residue at 60°C in vacuo to obtain 1,3,6',3"-tetra-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C1a which is used without further purification in the procedure of following Example 1D.
  • D. Dissolve the l,3,6',3"-tetra-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C1a prepared in Example 1C in dry tetrahydrofuran (12 ml) and add this solution dropwise to a stirred solution of sodium (1.5 g) in liquid ammonia (70 ml). Stir the reaction mixture for 10 minutes, then add methanol (20 ml) and water (100 ml) and evaporate in vacuo to a volume of about 75 ml. Pour onto excess IRC-50 (H ⊕) resin, wash the resin with water, then elute with 1 N ammonium hydroxide. Evaporate the combined, like eluates containing the desired product as determined by thin layer chromatography, evaporate, and chromatograph the resultant residue on silica gel (50 g) eluting with solvent mixture comprising chloroform: methanol:concentrated ammonium hydroxide (2:1:0.2). Again evaporate the combined eluates containing the desired product as determined by thin layer chromatography', dissolve the resultant residue in water and pass through IRA-401 (OH⊖) resin. Lyophilize the combined eluates to a residue of 2'-hydroxy-2'-desaminogentamicin Cla; yield 971 mg, 67 % theory; m.p. 110 - 114°C;
    Figure imgb0007
    + 162.4° (water, c=0.33). Combustion analysis: Found: C, 49.2; H, 8.5; N, 11.8. C19H38N408.H20 req. C, 49.7; H, 8.6; N, 12.0 %. pmr spectrum in deuterium oxide: 1.16 (s, 3, 4"-CCH3), 2.47 (s, 3, 3"-NCH3), 3.75 (dd, J1"2"=4 Hz, J2"3"=10.5 Hz, 1, H2"), 4.00 (d, J5"aX5"eq=12.5 Hz, 1, H5"eq). 5.04 (d, H1"2"=4 Hz, 1, H1") and 5.18 (d, H1'2'= 3.5 Hz, 1, H1,).
  • EXAMPLE 2 1-N-(AMINOHYDROXYALKALNOYL)-2'-HYDROXY-2'-DESAINO-GENTAMICIN C1a A. 3',6'-Di-N-Benzyloxycarbonyl-2'-Hydroxy-2'-DesaminoGentamicin C la
  • Stir a solution of 2'-hydroxy-2'-desaminogentamicin C1a (710 mg) in dimethylsulfoxide (28 ml) at room temperature, then add powdered cupric acetate (600 mg) and nickelous acetate (750 mg). Continue stirring for 30 minutes, then add dropwise a solution of N-(benzyloxycarbonyloxy) phthalimide (1.05 g) in dry dimethylsulfoxide (6 ml) and continue stirring for 15 minutes. Add the reaction solution to aqueous ammonium hydroxide (2 N; 250 ml) and extract with chloroform (three 150 ml portions). Wash the combined organic extracts with water (50 ml), dry over potassium carbonate, filter and evaporate to a residue comprising 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin Cla, which is used without further purification in aqueous methanol in the procedure of Example 2B(1).
  • B. 3,6'-Di-N-Benzyloxycarbonyl-1-N-[S-γ-(benzyloxycarbonylamino)-a-Hydroxybutyryl]-2'-hydroxy-2'-desaminogentamicin C la
    • (1) The requisite active ester reagent N-[S-γ-(benzyloxycarbonylamino)-a-hydroxybutyryloxy]succinimide in tetrahydrofuran is prepared as follows. To a stirred solution of S-γ-(benzyloxycarbonylamino)-α-hydroxybutyric acid (0.60 g) and dry N-hydroxysuccinimide (0.38 g) in dichloromethane (10 ml) and ethyl acetate (10 ml) add dropwise a solution of N,N-dicyclohexylcarbodiimide (0.50 g) in dichloromethane (5 ml). Stir the mixture overnight with the exclusion of moisture. Filter the reaction mixture and wash the insoluble with ethyl acetate. Evaporate the combined filtrate and ethyl acetate washings vacuo at 30°C. Dissolve the resultant residue comprising N-(S-γ-benzyloxycarbonylamino-α-hydroxy- butyryloxy)succinimide in dry tetryhydrofuran (15 ml).
    • (2) To a stirred solution of 3',6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C1a prepared in Example 2A in methanol (12 ml) and water (1.2 ml) add 10 ml of the tetrahydrofuran solution of N-[S-γ-(benzyloxycarbonylamino)-a-hydroxybutyryloxy]succinimide prepared in Example 2B(1) and stir the reaction mixture for 30 minutes, then add ammonium hydroxide (2 N; 10 ml) and evaporate the reaction mixture in vacuo to romove methanol and tetrahydrofuran- Extract the resultant residue with chloroform, dry the combined extracts over potassium carbonate, filter and evaporate. Chromatograph the resultant residue on silica gel (70 g) eluting with solvent mixture comprising chloroform:methanol:concentrated ammonium hydroxide (12:1:0.1) Combine the like eluates containing the desired product as determined by thin layer chromatography, evaporate and dry the resultant residue in vacuo at 60°G to obtain 3,6'-di-N-benzyloxycarbonyl-1-N-[S-γ-(benzyloxycarbonylamino)-a-hydroxybutyryl]-2'-hydroxy-2'-desaminogentamicin C1a as a white solid, yield 450 mg; 32 % theory; m.p. 200 - 202°C;
      Figure imgb0008
      + 51.1° (tetrahydrofuran, c=0.43). Combustion Analysis: Found: C, 57.2; H, 6.55; N, 6.9. Theory: C47H63N5O16.2H2O req C, 57.0; H, 6.8; N, 7.1 %.
    C. 1-N-(S-γ-Amino-α-Hydroxybutyryl)-2'-Hydroxy-2'-DesaminoGentamicin C1a (1-N-(S-γ-amino-α-hydroxybutyryl)-3',4'-Dideoxygentamicin B)
  • To 3,6'-di-N-benzyloxycarbonyl-1-N-[S-γ-(benzyloxycarbonylamino)-α-hydroxybutyryl]-2'-hydroxy-2'-desaminogentamicin C1a (400 mg) in tetrahydrofuran (30 ml) and water (4 ml) add acetic acid (0.25 ml) and 5 % palladium-on-carbon (500 mg) and shake the reaction mixture at one atmosphere of hydrogen for 24 hours. Dilute the reaction mixture with water, separate the catalyst by filtration and wash with 2 N ammonium hydroxide. Evaporate the combined filtrate and washings in vacuo, dissolve the resultant residue in water and pass down a column of IRA-401S (OH⊖) resin eluting slowly with water. Collect the eluates under nitrogen, combine the like eluates containing the desired product as determined by thin layer chromatography and lyophilize the combined eluates to obtain 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'- desaminogentamicin C1a as a white amorphous solid, yield 156 mg, 70 % theory; m.p. 70 - 80°C;
    Figure imgb0009
    + 109.5° (water, c=0.25). pmr. in D20 1.17 (s, 3,4"-CCH3), 2.47 (s, 3,3"-NCH3), 4.08 (d, J5"ax5"eq=13 Hz, 1, H5"eq), 4.18 (dd, 1, H2"'), 5.09 (d, JH1"2"=4 Hz, 1, H1") and 5.29 (dd, H1'2'=4 Hz, 1, H1').
  • D. 1-N-(S-β,-Amino-α-hydroxypropionyl)-2'-Hydroxy-2'-DesaminoGentamicin C1a (1-N-(S-β-amino-a-Hydroxypropionyl)-3',4'-Dideoxygentamicin B)
  • Prepare a solution of N-[S-β-(benzyloxycarbonylamino)-α-hydroxypropionyloxy]succinimide in tetrahydrofuran from S-β-(benzyloxycarbonylamino)-α-hydroxypropionic acid and dry N-hydroxysuccinimide in a manner similar to that described in Example 2B(1) and add dropwise to a solution of 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C1a in aqueous methanol and isolate and purify the resultant product in a manner similar to , that described in Example 2B(2) to obtain 3,6'-di-N-benzyloxycarbonyl-1-N-[S-β-(benzyloxycarbonylamino)-α-hydroxypropionyl]-2'-hydroxy-2'-desaminogentamicin C1a. Hydrogenate the foregoing 3'',6'-di-N-benzyloxycarbonyl derivative in aqueous tetrahydrofuran in the presence of palladium-on-carbon in a manner similar to that described in Example 2C to obtain 1-N-(S-β-amino-α-hydroxypropio- nyl)-2'-hydroxy-2'-desaminogentamicin Cla.
  • E. 1-N-(S-δ-Amino-α-hydroxyvaleryl)-2'-Hydroxy-2'-DesaminoGentamicin Cla (1-N-(S-δ-amino-α-hydroxyvaleryl)-3',4'-Dideoxygentamicin B)
  • In a manner similar to that described in Example 2B(1), prepare a solution of N-[S-δ-(benzyloxycarbonylamino)-a-hydroxyvaleryl]succinimide in tetrahydrofuran from S-δ-benzyloxycarbonylamino-a-hydroxyvaleric acid and dry N-hydroxysuccinimide, then add this solution dropwise to a solution of 3',6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin Cla in aqueous methanol in a manner similar to that described in Example 2B(2). Isolate and purify the resultant product in a manner similar to that described to obtain 3,6'-di-N-benzyloxycarbonyl-1-N-[S-δ-(benzyloxycarbonylamino)-α-hydroxy- valeryl]-2'-hydroxy-2'-desaminogentamicin C1a. Hydrogenate the foregoing 3',6'-di-N-benzyloxycarbonyl derivative in aqueous tetrahydrofuran in the presence of palladium-on-carbon in a manner similar to that described in Example 2C to obtain 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-desaminogentamicin Cla.
  • EXAMPLE 3 2'-HYDROXY-2'-DESAMINOSISOMICIN A. l,3,6'-Tri-N-Benzoyl-3"-N-Acetyl-2'-Oximino-2'-Desaminosisomicin
  • Stir a solution of l,3,6'-tri-N-benzoyl-3"-N-acetyl- sisomicin (8.9 g) in methanol (130 ml) and water (10 ml) with aqueous hydrogen perioxide (50 %, 4 ml), then add a solution of sodium tungstate (0.25 g) in water (3 ml). Stir the reaction mixture at room temperature maintaining a pH of about 9 - 10 by periodic small additions of aqueous sodium hydroxide solution (10 % w/v). After 3 hours, add additional hydrogen peroxide (1 ml) and sodium tungstate (0.12 g) and stir the reaction mixture overnight at room temperature. Add acetic acid (2 ml) to the reaction mixture, then pour the mixture into water (1 liter). Decant the aqueous mixture from the solid residue, rinse the solid residue with water and retain the residue. Combine the aqueous mixture with the water washings and extract with a chloroform:isopropanol (4:1) solvent mixture (three portions of 300 ml). Dissolve the original solid residue in the combined organic solvent extracts, dry the solution over sodium carbonate, filter and evaporate. Chromatograph the resultant residue on silica gel (200 g) eluting with a solvent mixture comprising chloroform:methanol:ammonium hydroxide (10:1:0.1),. Combine the like fractions containing the desired product as determined by thin layer chromatography and evaporate to a residue comprising 1,3,6'-tri-N-benzoyl-3"-N-acetyl-2'-oximino-2'-desaminosisomicin, yield 3.1 g, which is used without further purification in the procedure of following Example 3B.
  • B. 2'-Hydroxy-2'-Desaminosisomicin
  • To a stirred solution of 1,3,6'-tri-N-benzoyl-3"-N-acetyl-2'-oximino-2'-desaminosisomicin prepared in Example 3A (3.1 g) in ethanol (50 ml) and water (20 ml), add sodium bisulfite (5 g) and stir at reflux temperature for 1 hour. Add acetic acid (6 ml) and water (15 ml) and subject the solution to slow distillation for 15 minutes, then cool. To the cooled solution containing l,3,6'-tri-N-benzoyl-3"-N-acetyl-2'-oxo-2'-desaminosisomicin, add sodium carbonate (7.5 g) in small portions with stirring followed by sodium borohydride (1.7 g) in small portions. Stir the reaction mixture overnight, then dilute with isopropanol (400 ml), filter, wash the insoluble salts with isopropanol, then evaporate the combined filtrate and washings in vacuo to a residue comprising 1,3,6'-tri-N-benzoyl-3"-N-acetyl-2'-hydroxy-2'-desaminosisomicin.
  • To the foregoing residue add a solution of sodium hydroxide (7 g) in water (50 ml) and heat at reflux temperature under an atmosphere of argon for 60 hours. Cool, add dilute sulfuric acid until the solution is at a pH of about 10 and pour onto excess IRC-50 (H ) resin. Wash the resin with water, then elute with an excess of 1 N ammonium hydroxide. Evaporate the combined eluates and chromatograph the resultant residue on silica gel (100 g) eluting with the lower phase of a chloroform:methanol: 15 % ammonium hydroxide (2:1:1) solvent mixture. Evaporate the combined, like fractions containing the desired product as determined by thin layer chromatography, dissolve the resultant residue in water and pass through a short column of IRA-401S (OH) resin. Elute with water and lyophilize the eluates to obtain 2'-hydroxy-2'-desaminosisomicin as a white amorphous solid.
  • EXAMPLE 4 1-N-(AMINOHYDROXYALKANOYL)-2'-HYDROXY-2'-DESAMINOSISOMICIN A. 3,6'-Di-N-Benzyloxycarbonyl-2'-Hydroxy-2'-Desaminosisomicin
  • In a manner similar to that described in Example 2A, treat 2'-hydroxy-2'-desaminosisomicin in dimethylsulfoxide with cupric acetate and nickelous acetate followed by treatment with N-(benzyloxycarbonyloxy)phthalimide, and then reaction with aqueous ammonium hydroxide. Isolate and purify the resultant product in a manner similar to that described to obtain 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminosisomicin.
  • B. 3,6'-Di-N-Benzyloxycarbonyl-1-N-(S-Benzyloxycarbonylamino-a-Hydroxyalkanoyl)-2'-Hydroxy-2'-Desaminosisomicin
  • In a manner similar to that described in Examples 2B(2), 2C and 2D, treat a solution of 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminosisomicin in aqueous methanol with each of N-[S-γ-(benzyloxycarbonylamino)-α-hydroxy- butyryloxy]succinimide, N-[S-a-(benzyloxycarbonylamino)-a-hydroxypropionyloxy]succinimide, and N-[S-δ-(benzyloxycarbonylamino)-a-hydroxyvaleryloxy]succinimide. Isolate and purify each of the resultant products in a manner similar to that described in Example 3B(2) to obtain, respectively, 3,6'-di-N-benzyloxycarbonyl-1-N-[S-γ-(benzyloxycarbonylamino)-a-hydroxybutyryl]-2'-hydroxy-2'-desaminosisomicin, 3,6'-di-N-benzyloxycarbonyl-1-N-[S-β-(benzyloxycarbonylamino)-α-hydroxypropyl]-2'-hydroxy-2'-desaminosisomicin, and 3,6'-di-N-benzyloxycarbonyl-1-N-[S-δ-(benzyloxycarbonylamino)-α-hydroxyvaleryl]-2'-hydroxy-2'-desaminosisomicin.
  • C. 1-N-Aminohydroxyalkanoyl-2'-Hydroxy-2'-Desaminosisomicin
  • In a manner similar to that described in Example lD, treat a solution of each of the compounds prepared in Example 4B in tetrahydrofuran with sodium in liquid ammonia, then isolate and purify each of the resultant products in a manner similar to that described in Example 1D to obtain, respectively, 1-N-(S-γ-amino-α-hydroxybutyryl]-2'-hydroxy-2'-desaminosisomicin, 1-N-[S-0-amino-a-hydroxypropyl]-2'-hydroxy-2'-desaminosisomicin, and 1-N-[S-δ-amino-α-hydroxyvaleryl]-2'-hydroxy-2'-desaminosisomicin.
  • EXAMPLE 5 2'-HYDROXY-2'-DESAMINOGENTAMICIN C1 A. 1,3,6',3"-Tetra-N-Ethoxycarbonyl-2'-Oximino-2'-Desaminogentamicin C1
  • To a solution of 1,3,6',3"-tetra-N-ethoxycarbonylgentamicin C1 (0.5 g, 0.652 mmol) in methanol (6 ml) add sodium tungstate dihydrate (21.5 mg) in water (1 ml), then add hydrogen peroxide (0.2 ml, 30 % solution). Stir, add additional methanol to complete solution, adjust the pH from 4.8 to 7.8 by the dropwise addition of 2 N sodium hydroxide, then add additional sodium tungstate dihydrate (60 mg) in water (1 ml) and adjust the pH to 10.5 by the dropwise addition of 2 N sodium hydroxide. Continue stirring at room temperature for 2 hours. Extract the reaction mixture with chloroform (three portions of 75 ml), dry over magnesium sulfate and evaporate in vacuo to a residue comprising 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-oximinogentamicin C1 (yield 0.3 g) which is used without further purification in the procedure of Example 5B.
  • B. 1,3,6',3"-Tetra-N-Ethoxycarbonyl-2'-Oxo-2'-Desaminogentamicin C1.
  • To a solution of 1,3,6',3"-tetra-N-ethoxycarbonyl-2'- oximino-2'-desaminogentamicin C1 (0.1 g) in acetonitrile (0.3 ml) add 1 N hydrochloric acid (0.28 ml) containing acetaldehyde (0.02 ml) followed by water ( 5 ml). Extract the reaction mixture with ethyl acetate (three portions of 15 ml), dry over magnesium sulfate and evaporate in vacuo to a residue comprising 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-oxo-2'-desaminogentamicin C1 (yield 80 mg) which is used without further purification in the procedure of Example 5C.
  • C. 1,3,6',3"-Tetra-N-Ethoxycarbonyl-2'-Hydroxy-2'-Desaminogentamicin C 1
  • To a solution of 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-oxo-2'-desaminogentamicin C1 (80 mg) in dioxane (2 ml) and water (2 ml) at 0°C with stirring add dropwise a solution of sodium borohydride (50 mg) in aqueous dioxane (1:1, 2 ml). Add acetone (3 ml) followed by water (5 ml). Extract with ethyl acetate (three portions of 15 ml), dry over magnesium sulfate and evaporate in vacuo to a residue comprising 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-hydroxy-2'-desaminogentamicin Cl, which is used without further purification in the procedure of following Example 5D.
  • D. 2'-Hydroxy-2'-Desaminogentamicin C1
  • To a solution of 1,3,6',3"-tetra-N-ethoxycarbonyl-2'-hydroxy-2'-desaminogentamicin C1 (1.21 g) in dimethylsulfoxide (16 ml) add a solution of potassium hydroxide (2 g) in water (3 ml) at 25°C. Stir at room temperature for 16 hours, then add 2 N sulfuric acid dropwise until the solution is at about pH 10.5. Filter, dilute the reaction solution with water (50 ml), then add IR-50 (H) resin until the reaction mixture is at pH 5. Filter the resin, wash the resin with water (200 ml) discarding the water washing. Wash the resin with 2 N ammonium hydroxide and evaporate the ammonium hydroxide solution in vacuo. Dissolve the resultant residue in 10 % aqueous sodium hydroxide (5 ml) and heat in a teflon bomb for 16 hours at 80°C, then for 16 hours at 120°C. Acidify the reaction mixture to a pH of about 11 with 2 N sulfuric acid, filter, then add IR-50 (H) resin until the reaction mixture is at a pH of about 4.5. Filter, wash the resin with water, discarding the water wash, then wash the resin with 2 N ammonium hydroxide. Evaporate the ammonium hydroxide wash in vacuo, dissolve the resultant residue in 90 % hydrazine hydrate and heat at reflux temperature for 16 hours. Evaporate, chromatograph the resultant residue over silica gel eluting with a solvent mixture comprising chloroform:isopropanol:17 % ammonium hydroxide (2:1:1). Combine the like eluates containing the desired product as determined by thin layer chromatography and evaporate to a residue of 2'-hydroxy-2'-desaminogentamicin C1; 479 (M+1)+, 478 (M.+), 421, 348, 330, 320, 302, 350,.332, 322, 304, 160, 158. PMR (100 MHz, D20) 60.97 (3H, d, J=6.3 Hz, CH3-CH), 1.14 (3H, s, CH3-C4"), 2.24 (3H, s, CH3-N), 2.43 (3H, s, CH3-N), 3.27 (lH, d, J=12.5 Hz, H-5"ax), 3.73 (lH, q, J=4, 10 Hz, H-2"), 3.99 (lH, d, J=12.5 Hz, 5"eq), 5.01 (lH, d, J=4, H-l"), 5.12 (lH, d, J=3.5, H-l') ppm.
  • EXAMPLE 6 1-N-(AMINOHYDROXYALKANOYL)-2'-HYDROXY-2'-DESAMINOGENTA-MICIN C1 A. 3,6'-Di-N-Benzyloxycarbonyl-2'-Hydroxy-2'-Desaminogentamicin C1
  • To a solution of 2'-hydroxy-2'-desaminogentamicin C1 (0.79) in dimethylsulfoxide (31.6 ml), add cupric acetate dihydrate (490 mg) and nickelous acetate tetrahydrate (6.16 mg). Stir until solution is complete, then add N-(benzyloxycarbonyloxy)phthalimide (1.147 g). Follow the course of the reaction via thin layer chromatography, adding 2 additional 50 mg portions of N-(benzyloxycarbo- nyloxy)phthalimide at intervals. When one new major spot has appeared on the thin layer chromatogram, add 2 N ammonium hydroxide (250 ml), extract with methylene chloride (eight portions of 100 ml), wash the methylene chloride extracts with water, then dry over magnesium sulfate and evaporate in vacuo to a residue comprising 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C1, which is used without further purification in the procedure of Example 6B.
  • B. 3,6'-Di-N-Benzyloxycarbonyl-1-N-[S-β-(benzyloxycarbonylamino)-a-Hydroxypropionyl]-2'-Hydroxy-2'-Desaminogentamicin C1
  • To a solution of the 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C1 prepared in Example 6A in methanol (20 ml) and water (2 ml), with stirring add N-(S-β-benzyloxycarbonylamino-α-propionyloxy)succiniznide (1.5 equivalents in three equal portions). Extract with methylene chloride (three portions of 150 ml), dry over magnesium sulfate, and evaporate, chromatograph the resultant residue over silica gel (40 g) eluting with a solvent mixture comprising chloroform:methanol:ammonium hydroxide (2:1:1). Combine the like fractions containing the desired product as determined by thin layer chromatography and evaporate the combined eluates in vacuo to a residue comprising 3,6'-di-N-benzyloxycarbonyl-1-N-[S-β-(benzyloxycarbonylamino)-a-hydroxypropionyl]-2'-hydroxy-2'-desaminogentamicin C1, yield 0.34 g. Combustion Analysis: Found: C, 58.93; H, 6.48; N, 7.08. Theory: W48H65N5C16·H2O C, 59.01; H, 6.81; N,7.17.
  • C. 1-N-(S-β-Amino-α-Hydroxypropionyl)-2'-Hydroxy-2'-Desaminogentamicin C 1
  • To a solution of 3,6'-di-N-benzyloxycarbonyl-1-N-[S-β-(benzyloxycarbonylamino)-a-hydroxypropionyl]-2'-hydroxy-2'-desaminogentamicin C1 (0.3 g) in aqueous tetrahydrofuran (1:10) (15 ml), add acetic acid (0.15 ml) and hydrogenate in the presence of 5 % palladium-on-charcoal (200 mg) at 60 psc for 16 hours. Filter, evaporate the filtrate and chromatograph the resultant residue over silica gel (2 g) eluting with a solvent mixture comprising chloroform:methanol:ammonium hydroxide (3:4:2). Combine the like eluates containing the desired product as determined by thin layer chromatography and evaporate in vacuo to a residue comprising 1-N-(S-β-amino-α-hydroxypro- pionyl)-2'-hydroxy-2'-desaminogentamicin Cl. Further purify by dissolving in water, pouring the aqueous solution over IRA-401S (OH) resin (0.6 ml) eluting slowly with water. Collect the eluates under nitrogen and freeze dry the combined eluates to obtain 1-N-(S-γ-amino-α-hydroxy- propionyl)-2'-hydroxy-2'-desaminogentamicin Cl, yield 75.7 mg,
    Figure imgb0010
    + 99.7° (water, c=0.32). Combustion Analysis: C, 46.73; H, 7.81; N, 10.74. Calculated C24H47N5O16·1.5H2CO3, C, 46.5; H, 7.65; N, 10.63; PMR (100 MHz, D2O) δ 0.99 (3H, d, J=6.8 Hz, CH3-CH), 1.13 (3H, s, CH3-C4"), 2.27 (3H, s, CH3-N), 2.43 (3H, s, CH3-N), 5.03 (1H, d, J=3.5, H-l"), 5.15 (lH, d, J=3.7 Hz, H-1') ppm.
  • D. In a manner similar to that described in Example 6B, treat 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desaminogentamicin C1 with each of N-(S-γ-benzyloxycarbonylamino-α-hydroxybutyryloxy)succinimide and N-(S-δ-benzyloxycarbonylamino-α-hydroxyvaleryloxy)succinimide and iso- late and purify each of the resultant products in the described manner to obtain 3,6'-di-N-benzyloxycarbonyl-1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C1 and 3,6'-di-N-benzyloxycarbonyl-l-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-desaminogentamicin Cl, respectively. Hydrogenate each of the foregoing products in the presence of 5 % palladium-on-charcoal in a manner similar to that described in Example 6C and isolate and purify each of the resultant products to obtain, respectively, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C1 and 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-desaminogentamicin C 1.
  • EXAMPLE 7 OTHER 2'-HYDROXY-2'-DESAMINO AMINOGLYCOSIDES
  • A. Subject each of the 1,3,6',3"-tetra-N-benzyloxycarbonyl- aminoglycoside derivatives prepared in Preparations 6 and 7 to a series of reactions similar to that described in Examples 1A-1D to obtain, respectively, 2'-hydroxy-2'-desaminotobramycin, 2'-hydroxy-2'-desaminogentamicin C2, 2'-hydroxy-2'-desaminogentamicin C2a, 2'-hydroxy-2'-desamino-3',4'-dideoxykanamycin A (also named 3',4'- dideoxy-kanamycin A), 2'-hydroxy-2'-desamino-Antibiotic JI-20A (also named gentamicin B), and 2'-hydroxy-2'- desamino-Antibiotic JI-20B.
  • B. Subject 1,3,6',3,"-tetra-N-ethoxycarbonylgentamicin C2b to a series of reactions similar to that described in Examples5A - 5D and isolate and purify the resultant product in a manner similar to that in Example 5D to obtain 2'-hydroxy-2'-desaminogentamicin C2b.
  • C. Subject each of the l,3,6'-tri-N-benzoyl-3"-N-acetyl- aminoglycoside derivatives prepared in Preparation 5 to a series of reactions similar to those described in Example 3, and isolate and pruify each of the resultant products in a manner similar to that described in Example 3B to obtain, respectively, 2'-hydroxy-2'-des- amino-Antibiotic G-52, 2'-hydroxy-2'-desamino-Antibiotic 66-40D, 2'-hydroxy-2'-desamino-Antibiotic 66-40B, 2'-hydroxy-2'-desaminoverdamicin, 2'-hydroxy-2'-des- amino-Antibiotic Mu-1, 2'-hydroxy-2'-desamino-5-deoxysisomicin, 2'-hydroxy-2'-desamino-Antibiotic Mu-41 2'-hydroxy-2'-desamino-5-episisomicin, 2'-hydroxy-2'-des- amino-5-epi-azido-5-deoxysisomicin, and 2'-hydroxy-2'- desamino-1-N-ethylsisomicin.
  • EXAMPLE 8 1-N-(ω-AMINO-α-HYDROXYALKANOYL)-2'-HYDROXY-2'-DESAMINO AMINOGLYCOSIDE DERIVATIVES A. 3,6'-Di-N-Benzyloxycarbonyl-2'-Hydroxy-2'-Desamino Aminoglycosides
  • In a manner similar to that described in Example 2A, treat each of the 2'-hydroxy-2'-desamino aminoglycosides prepared in Examples 7A, 7B and 7C with powdered cupric acetate and nickelous acetate followed by treatment with N-(benzyloxycarbonyloxy)phthalimide. Isolate and purify each of the resultant products in a manner similar to that described to obtain the corresponding 3',6'-di-N-benzyloxycarbonyl derivative.
  • B. 3,6'-Di-N-Benzyloxycarbonyl-1-N-[S-ω-(benzyloxycarbonyl- ainino)-α-Hydroxyalkanoyl]-2'-Hydroxy-2'-Desamino Aminoglycosides (1) 3,6'-Di-N-Benzyloxycarbonyl-1-N-[S-γ-(benzyloxycarbonylamino)-a-Hydroxybutyryl]-2'-Hydroxy-2'-Desamino Aminoglycosides
  • In a manner similar to that described in Example 2B(2), treat each of the 3,6'-di-N-benzyloxycarbonyl- 2'-hydroxy-2'-desamino aminoglycosides prepared in Example 8A with N-(S-Y-benzyloxycarbonylamino-a-hyd- roxybutyryloxy)succinimide, then isolate and purify each of the resultant products in a manner similar to that described to obtain the corresponding 1-N-[S-γ-(benzyloxycarbonylamino)-α-hydroxybutyryl] derivative.
  • (2) 3,6'-Di-N-Benzyloxycarbonyl-1-N-β-(benzyloxycarbonylamino)-a-hydroxypropionyl]-2'-Hydroxy-2'-Des- amino Aminoglycosides
  • In a manner similar to that described in Examples 2D and 6B, treat each of the 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desamino aminoglycosides prepared in Examples 7A, 7B and 7C with N-(S-0-benzyloxycarbonylamino-a-hydroxypropionyldxy)succinimide and isolate and purify each of the resultant products in a manner similar to that described to obtain 1-N-[S-β-(benzyloxycarbonylamino)-a-hydroxypropionyl] derivative.
  • (3) 3,6'-Di-N-Benzyloxycarbonyl-1-N-[S-δ-(benzyloxycarbonylamino)-a-Hydroxyvaleryl]-2'-Hydroxy-2'-Desamino Aminoglycosides
  • In a manner similar to that described in Example 2E, , treat each of the 3,6'-di-N-benzyloxycarbonyl-2'-hydroxy-2'-desamino aminoglycoside derivatives prepared in Examples 7A, 7B and 7C with N-(S-δ-benzyloxycarbonylamino-a-hydroxyvaleryl)succinimide and isolate and purify each of the resultant products in a manner similar to that described to obtain, respectively, the 1-N-[S-δ-(benzyloxycarbonylamino)-α-hydroxy- valeryl] derivative.
  • C. 1-N-(S-ω-Amino-α-Hydroxyalkancyl)-2'-Hydroxy-2'-Desamino Aminoglycosides
    • (1) In a manner similar to that described in Example 2C, hydrogenate each of the 3,6'-di-N-benzyloxycarbonyl-1-N-[S-ω-(benzyloxycarbonylamino)-α-hydroxyalkanoyl]-2'-hydroxy-2'-desamino aminoglycoside derivatives prepared in Example 8B(1), (2) and (3) which were derived from the products of Examples 7A and 7B, isolate and purify each of the resultant products in a manner similar to that in Example 2C to obtain, respectively, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-des- aminotobramycin, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C2, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C2a, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-des- amino-3',4'-dideoxykanamycin B, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C2b; 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'- desaminotobramycin, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C2, 1-N-(S-β-amino- a-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C2a, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'- desamino-3',4'-dideoxykanamycin B, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C2b; 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'- desaminotobramycin, 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-desaminogentamicin C2, 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-desaminogentamicin C2a, 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'- desamino-3',4'-dideoxykanamycin B, 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-desaminogentamicin C2b.
    • (2) In a manner similar to that described in Example 1D, treat each of the 3,6'-di-N-benzyloxycarbonyl-l-N-[S-ω-(benzyloxycarbonylamino)-α-hydroxyalkanoyl]-2'-hydroxy-2'-desamino aminoglycosides prepared in Example 8B(1), (2), and (3) which were derived from the products of Example 7C with sodium in liquid ammonia. Isolate and purify each of the resultant products in a manner similar to that described to obtain, respectively, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'- desamino-Antibiotic G-52, 1-N-(S-Y-amino-a-hydroxy- butyryl)-2'-hydroxy-2'-desamino-Antibiotic 66-40D, 1-N-(S-γ-amino-α-hydroxybutyryl-2'-hydroxy-2'-des- amino-Antibiotic 66-40B, 1-N-(S-γ-amino-α-hydroxybu- tyryl)-2'-hydroxy-2'-desaminoverdamicin, 1-N-(S-γ-amino-a-hydroxybutyryl)-2'-hydroxy-2'-desamino-Antibiotic Mu-1, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desamino-5-deoxysisomicin, 1-N-(S-γ-amino- a-hydroxybutyryl)-2'-hydroxy-2'-desamino-Antibiotic Mu-4, 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'- desamino-5-episisomicin, 1-N-(S-γ-amino-α-hydroxy- butyryl)-2'-hydroxy-2'-desamino-5-epi-azido-5-deoxysisomicin, and 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desamino-1-N-ethylsisomicin; 1-N-(S-β-amino- a-hydroxypropionyl)-2'-hydroxy-2'-desamino-Antibiotic G-52, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desamino-Antibiotic 66-40D, 1-N-(S-a-amino-a-hydro- xypropionyl)-2'-hydroxy-2'-desamino-Antibiotic 66-40B, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-des- aminoverdamicin, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desamino-Antibiotic Mu-1, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desamino-5-deoxysisomicin, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desamino-Antibiotic Mu-4, 1-N-(S-β-amino-α-hydroxy- propionyl)-2'-hydroxy-2'-desamino-5-episisomicin, 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desamino-5-epi-azido-5-deoxysisomicin, and 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desamino-l-N-ethylsisomicin; 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'- desamino-Antibiotic G-52, 1-N-(S-δ-amino-α-hydroxy- valeryl)-2'-hydroxy-2'-desamino-Antibiotic 66-40D, 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-des- amino-Antibiotic 66-40B, 1-N-(S-δ-amino-α-hydroxyva- leryl)-2'-hydroxy-2'-desaminoverdamicin, 1-N-(S-δ-amino-a-hydroxyvaleryl)-2'-hydroxy-2'-desamino-Antibiotic Mu-1, 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-desamino-5-deoxysisomicin, 1-N-(S-δ-amino- a-hydroxyvaleryl)-2'-hydroxy-2'-desamino-Antibiotic Mu-4, 1-N-(S-δ-amino-α-hydraxyvaleryl)-2'-hydroxy-2'- desamino-5-episisomicin, 1-N-(S-δ-amino-α-hydroxyva- leryl)-2'-hydroxy-2'-desamino-5-epi-azido-5-deoxysisomicin, and 1-N-(S-δ-amino-α-hydroxyvaleryl)-2'-hydroxy-2'-desamino-l-N-ethylsisomicin.
    EXAMPLE 9 ACID ADDITION SALTS A. Sulfate Salts (Sulfuric Acid Addition Salts)
  • Dissolve 5.0 g of 2'-hydroxy-2'-desaminogentamicin C1a in 25 ml water and adjust the pH of the solution to 4.5 with 1 N sulfuric acid. Pour into about 300 ml of methanol with vigorous agitation, continue the agitation for about 10 - 20 minutes and filter. Wash the precipitate with methanol and dry at about 60°C in vacuo to obtain 2'-hydroxy-2'-desaminogentamicin C1a sulfate.
  • In like manner, the sulfate salt of the compounds of Examples 2 to 8 are prepared.
  • B. Hydrochloride Salts
  • Dissolve 5.0 g of 2'-hydroxy-2'-desaminogentamicin C1a in 2'5 ml of water. Acidify with 2 N hydrochloric acid to pH 5. Lyophilize to obtain 2'-hydroxy-2'-desaminogentamicin C1a hydrochloride.
  • In like manner, the hydrochloride salt of the compounds of Examples 2 to 8 are prepared.
  • The 21-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols of this invention (particularly those wherein the 6-0-aminoglycosyl is 6-O-garosaminyl and wherein the 1,3-diaminocyclitol is 2-deoxystreptamine) and their non-toxic, pharmaceutically acceptable acid addition salts, in general, exhibit broad spectrum antibacterial activity and possess an improved antibacterial spectrum compared to that of the parent antibiotics. This improved spectrum consists of enhanced potency of the claimed compounds against organisms resistant to the parent compound. Thus, for example, compounds of this invention, e.g. 2'-hydroxy-2'-desamino-4-O-aminogly- cosyl-6-0-garosaminyl-2-deoxystreptamines, are more active against organisms which inactivate the parent antibiotics by acetylation of the 2'-amino group. In addition to the foregoing, the 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and their non-toxic, pharmaceutically acceptable acid addition salts are, in general, less acutely toxic than their precursor 2'-amino parent antibiotics.
  • Particularly valuable are 2'-hydroxy-2'-desamino-gentamicin C1 and 2'-hydroxy-2'-desaminogentamicin C1a, which derivatives are broad spectrum antibacterial agents, being active against gram positive bacteria (e.g. Staphylococcus aureus) and gram negative bacteria (e.g. Escherichia coli and Pseudomonas aeruginosa) as determined by standard dilution tests, including,bacteria resistant to the parent compound.
  • Most valuable compounds of this invention are the 1-N-(ω-amino-a-hydroxy) derivatives of 2'-hydroxy-2'-desaminogentamicin Cla' particularly 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C1a and 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C1a which exhibit broader spectra of antibacterial activity than the precursor 1-N-unsubstituted-2'-hydroxy-2'-desaminogentamicin Cla or the corresponding 1-N-(S-ω-amino-α-hydroxyalkanoyl) gentamicin Cla. These preferred compounds possess improved potency versus bacteria resistant to the aforementioned precursor compounds, being active against 2"-adenylating and 3-acetylating strains of bacteria. Additionally, the foregoing 1-N-(ω-amino-α-hydroxy) derivatives of 2'-hydroxy-2'- desaminogentamicin C1a are advantageously less acutely toxic than the corresponding 1-N-(ω-amino-α-hydroxy)gentamicin C1a.
  • The 2'-hydroxy-2'-desamino compounds of this invention can be used alone or in combination with other antibiotic agents to prevent the growth or reduce the number of bacteria in various environments. They may be used, for example, to disinfect laboratory glassware, dental and medical equipment contaminated with Staphylococcus aureus or other bacteria inhibited by the 2'-hydroxy-2'-desamino derivatives of this invention.
  • The activity of the 2'-hydroxy-2'-desamino-4,6-di-O-(amino- glycosyl)-l,3-diaminocyclitols against gram negative bacteria renders them useful for combatting infections caused by gram negative organisms, e.g. species of Proteus and Pseudomonas. The 2'-hydroxy-21-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, e.g. 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C1a and 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C1a, have veterinary applications, particularly in the treatment of mastitis in cattle and Salmonella-induced diarrhea in domestic animals such as the dog and the cat.
  • The dosage administered of the 2'-hydroxy-2'-desamino-4,6-di-0-(aminoglycosyl)-1,3-diaminocyclitols will be dependent upon the age and wieght of the animal species being treated, the mode of administration, and the type and severity of bacterial infection being prevented or reduced. In general, the dosage employed to combat a given bacterial infection will be similar to the' dosage requirements of the corresponding 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol.
  • The compounds of this invention may be administered orally. They may also be applied topically in the form of ointments, both hydrophilic and hydrophobic, in the form of lotions which may be aqueous, non-aqueous or of the emulsion type or in the form of creams. Pharmaceutical carriers useful in the preparation of such formulations will include, for example, such substances as water, oils, greases, polyesters, polyols and the like.
  • For oral administration, the compounds of this invention may be compounded in the form of tablets, capsules, elixirs or the like or may even be admixed with animal feed. It is in these dosage forms that the antibacterials are most effective for treating bacterial infections of the gastrointestinal tract, which infections cause diarrhea.
  • In general, the topical preparations will contain from about 0.1 to about 3.0 g of a 2'-hydroxy-2'-desamino-4,6-di-O-(amino- glycosyl)-1,3-diaminocyclitol derivative per 100 g of ointment, creams or lotion. The topical preparations are usually applied gently to lesions from about 2 to about 5 times a day.
  • The antibacterials of this invention may be dtilized in liquid form such as solutions, suspensions and the like for otic and optic use and may also be administered parenterally via intramuscular injection. The injectable solution or suspension will usually be administered at from about 1 mg to about 10 mg of antibacterial per kilogram of body weight per day divided into about 2 to about 4 doses. The precise dose depends on the stage and severity of the infection, the susceptibility of the infecting organism to the antibacterial and the individual characteristics of the animal species being treated.
  • The following formulations are to exemplify some of the dosage forms in which the antibacterial agents of this invention and their derivatives may be employed.
  • Formulation 1
  • Figure imgb0011
  • Procedure
  • Prepare a slurry consisting of the 1-N-(S-γ-amino-α-hydroxy- butyryl)-2'-hydroxy-2'-desaminogentamicin C1a, lactose and polyvinylpyrrolidone. Spray dry the slurry. Add the corn starch and magnesium stearate. Mix and compress into tablets.
  • Formulation 2
  • Figure imgb0012
  • Procedure
    • (1) Melt the petrolatum.
    • (2) Mix the 1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'- desaminogentamicin Cla, methylparaben and propylparaben with about 10 % of the molten petrolatum.
    • (3) Pass the mixture through a colloid mill.
    • (4) Add the remainder of the petrolatum with agitation and cool the mixture until it becomes semi-solid. At this stage the product may be put into suitable containers.
  • Ointments of other 2'-hydroxy-2'-desamino-4,6-di-o-(amino- glycosyl)-1,3-diaminocyclitols of this invention are prepared by substituting an equivalent quantity of 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol or an acid addition salt thereof, for.1-N-(S-γ-amino-α-hydroxy- butyryl)-2'-hydroxy-2'-desaminogentamicin C1a in the foregoing example and by following substantially the procedure of the example.
  • Formulation 3
  • Figure imgb0013
  • Procedure: For a 50.0 liter batch
  • Charge approximately 35 liters of water for injection to a suitable stainless steel jacketed vessel and heat to about 70°C. Charge the methylparaben and propylparaben to the heated water for injection and dissolve with agitation. When the parabens are completely dissolved, cool the contents of the tank to 25 - 30°C by circulating cold water through the tank jacket. Sparge the solution with nitrogen gas for at least 10 minutes and keep covered with nitrogen during subsequent processing. Charge and dissolve the disodium EDTA and sodium bisulfite. Charge and dissolve the 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin Cla sulfate. Bring the batch volume up to 50.0 liters with water for injection and agitate until homogeneous.
  • Under sterile conditions, filter the solution through a suitable bacteria retentive filter collecting the filtrate in a filling tank.
  • Fill the filtrate aseptically into sterile pyrogen-free multiple dose vials, stopper and seal.
  • In like manner, injectable solutions of other 2'-hydroxy-2'- desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and especially acid addition salts of such antibacterial agents, may be prepared by substituting an equivalent quantity of such compounds for 1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C1a sulfate and by following the procedure set forth above.

Claims (6)

1. Process for the preparation of a 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol having an amino function in position 6', characterized in that an appropriate 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol having an amino function in position 2' wherein all other amino functions are protected by a protecting group, is oxidized by means of hydrogen peroxide in an inert solvent in the presence of tungstate ion at a pH of about 9 to about 11, whereby the molar ratio of hydrogen peroxide to starting compound is at least 2:1; that the so-obtained 2'-oximino-4,6-di-O-(aminoglyeosyl)-1,3-diaminocyclitol is subjected to a cleavage of the oxime function; that the so-obtained 2'-oxo-4,6-di-0-(aminoglycosyl)-l,3-diaminocyclitol is reduced at the oxo group; and that the so-obtained compound is subjected to a removal of the protecting groups, followed, if desired and appropriate, by transformation into a 1-N-(α-amino-α-hydroxyalkanoyl)-, 1-N-CH2X-, 5-deoxy-, 5-epi-, 5-epi-azido-5-deoxy- and/or 5-epi-fluoro-5-deoxy-derivative, whereby X is as herein defined.
2. Process according to claim 1, characterized in that
a) the oxidation in the first step is carried out in an aqueous lower alkanol as a solvent;
b) the cleavage of the oxime function in the second step is carried out, preferably by means of sodium bisulfite followed by mild hydrolysis, or by treatment in an acidic hydrolytic medium in the presence of acetaldehyde;
c) the reduction in the third step is carried out by means of an alkali metal borohydride, preferably sodium borohydride; and
d) the amino protective groups are groups susceptible to reductive cleavage or to basic hydrolysis, preferably benzyloxycarbonyl, ethoxycarbonyl or methoxycarbonyl.
3. Process according to claim 1 or claim 2, characterized in that the starting compound used is Antibiotic JI-20A whereby the 2'-hydroxy-2'-desamino-Antibiotic JI-20A is obtained which is the same as gentamicin B.
4. 2'-Hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols having amino functions in positions 6' and 3" and hydroxyl groups in the positions 2" and 4", whenever prepared by the process of claim 1 or claim 2.
5. A 2'-hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol selected from the group consisting of
2'-hydroxy-2'-desaminogentamicin C1,
2'-hydroxy-2'-desaminogentamicin C1a,
2'-hydroxy-2'-desaminogentamicin C2,
2'-hydroxy-2'-desaminogentamicin C2a,
2'-hydroxy-2'-desaminogentamicin C2b'
2'-hydroxy-2'-desaminosisomicin,
2'-hydroxy-2'-desaminoverdamicin,
2'-hydroxy-2'-desamino-Antibiotic G-52,
2'-hydroxy-2'-desamino-Antibiotic 66-40B,
2'-hydroxy-2'-desamino-Antibiotic 66-40D,
2'-hydroxy-2'-desamino-Antibiotic JI-20B,
2'-hydroxy-2'-desaminotobramycin; and
2'-hydroxy-2'-desamino-3',4'-dideoxykanamycin B;
the 5-deoxy, 5-epi-, 5-epi-azido-5-deoxy derivatives thereof;
the 2'-hydroxy-2'-desamino-Antibiotic Mu-1 and
2'-hydroxy-2'-desamino-Antibiotic Mu-4; the 1-N-monosubstituted derivatives of the foregoing wherein the substituent R is either an (ω-amino-α-hydroxyalkanoyl) group having from 3 to 5 carbon atoms, or a group CH2X wherein X represents hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkylalkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, aminohydroxyalkyl, and alkylaminohydroxyalkyl, said aliphatic radicals having up to 7 carbon atoms, and, when substituted by both hydroxy and amino having said substituents attached to different carbon atoms; and the pharmaceutically acceptable acid addition salts thereof.
6. A compound according to claim 5, being a 1-N-(ω-amino- a-hydroxyalkanoyl) derivative of said 2'-hydroxy-2'-des- amino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitol.
7. A compound according to claim 6, being a 1-N-(ω-amino- a-hydroxyalkanoyl) derivative of a 2'-hydroxy-2'-desamino-4-0-garosaminyl-2-deoxystreptamine.
8. A compound according to claim 7, wherein the I-N-substituent is a β-amino-α-hydroxypropionyl- or a γ-amino-α-hydroxybutyryl-group.
9. Compounds according to claim 8, being:
1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C1;
1-N-(S-β-amino-α-hydroxypropionyl)-2'-hydroxy-2'-desaminogentamicin C la ;
1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C1; and
1-N-(S-γ-amino-α-hydroxybutyryl)-2'-hydroxy-2'-desaminogentamicin C1a;
and acid addition salts thereof.
10. A pharmaceutical composition comprising as an active ingredient a compound as defined in any one of claims 4 to 7.
EP78100207A 1977-06-24 1978-06-21 Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives Expired EP0000473B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80983977A 1977-06-24 1977-06-24
US809839 1977-06-24

Publications (2)

Publication Number Publication Date
EP0000473A1 true EP0000473A1 (en) 1979-02-07
EP0000473B1 EP0000473B1 (en) 1981-03-11

Family

ID=25202337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100207A Expired EP0000473B1 (en) 1977-06-24 1978-06-21 Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives

Country Status (5)

Country Link
EP (1) EP0000473B1 (en)
JP (1) JPS5412347A (en)
DE (1) DE2860513D1 (en)
DK (1) DK283478A (en)
IT (1) IT1097278B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013210A1 (en) * 1979-04-04 1980-11-20 Toyo Jozo Kk NEW AMINOGLYCOSIDE ANTIBIOTICS AND METHOD FOR THEIR PRODUCTION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2201872A1 (en) * 1972-10-10 1974-05-03 Scherico Ltd
FR2218879A2 (en) * 1973-02-23 1974-09-20 Bristol Myers Co
FR2289202A1 (en) * 1974-10-26 1976-05-28 Pfizer NEW AMINOGLYCOSIDES OF 2-DEOXYSTREPTAMINE, THEIR PREPARATION AND ANTIBACTERIAL COMPOSITION CONTAINING THEM
FR2293941A1 (en) * 1974-12-09 1976-07-09 Bristol Myers Co NEW DERIVATIVES OF KANAMYCINS A AND B AND THEIR PREPARATION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2201872A1 (en) * 1972-10-10 1974-05-03 Scherico Ltd
FR2218879A2 (en) * 1973-02-23 1974-09-20 Bristol Myers Co
FR2289202A1 (en) * 1974-10-26 1976-05-28 Pfizer NEW AMINOGLYCOSIDES OF 2-DEOXYSTREPTAMINE, THEIR PREPARATION AND ANTIBACTERIAL COMPOSITION CONTAINING THEM
FR2293941A1 (en) * 1974-12-09 1976-07-09 Bristol Myers Co NEW DERIVATIVES OF KANAMYCINS A AND B AND THEIR PREPARATION

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
REAGENTS FOR ORGANIC SYNTHESIS; Fieser and Fieser, vol. 1, Wiley 1967 New York. Page 475 *
STICKSTOFFVERBINDUNGEN I, Band 10, Teil 4, Houben-Weyl G.Thieme Verlag, Stuttgart 1968. Page 269 *
THE JOURNAL OF ANTIBIOTICS 27 (11) (1974) pages 851-858. *
THE JOURNAL OF ANTIBIOTICS 29(4) (1976) pages 319-353. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013210A1 (en) * 1979-04-04 1980-11-20 Toyo Jozo Kk NEW AMINOGLYCOSIDE ANTIBIOTICS AND METHOD FOR THEIR PRODUCTION

Also Published As

Publication number Publication date
EP0000473B1 (en) 1981-03-11
JPS5412347A (en) 1979-01-30
IT1097278B (en) 1985-08-31
IT7824904A0 (en) 1978-06-23
DE2860513D1 (en) 1981-04-09
DK283478A (en) 1978-12-25

Similar Documents

Publication Publication Date Title
US4044123A (en) 6'-N-alkyl-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, methods for their use as antibacterial agents and compositions useful therefor
US4136254A (en) Process of selectively blocking amino functions in aminoglycosides using transition metal salts and intermediates used thereby
US4002742A (en) 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor
US4085208A (en) Process for preparing 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 1-epimers and 1-N-alkyl derivatives produced thereby; methods for the use of the 1-epimer derivatives as antibacterial agents and compositions useful therefor
US4230847A (en) Aminoglycoside antibiotic compounds
US3920628A (en) 2{41 -Deoxyaminoglycosides and 2{41 -epi-amino-3{41 -desamino derivatives thereof, methods for their manufacture and novel intermediates useful therein
US4212859A (en) 2'-Hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, method for their use as antibacterial agents, and compositions useful therefor
US4002608A (en) 1-N-alkyl-aminoglycoside-XK-88 derivatives and methods for their manufacture
US4000261A (en) 5-epi-4,6-di-o-(aminoglycosyl)-2-deoxystreptamines, methods for their manufacture and intermediates useful therein, methods for their use as antibacterial agents and compositions useful therefor
NO139483B (en) ANALOGICAL PROCEDURE FOR PREPARING NEW PSEUDOTRISACCHARIDES
US4170642A (en) Derivatives of kanamycin A
US4169141A (en) 1-Peptidyl derivatives of di-O-aminoglycosyl-1,3-diaminocyclitol antibacterial agents
US4000262A (en) 5-epi-amino and 5-epi-azido-4,6-di-o-(aminoglycosyl)-2,5-dideoxystreptamines 1-n-alkyl-5-epi-amino and 1-n-alkyl-5-epi-azido-4,6-di-o-(aminoglycosyl)-2,5-dideoxystreptamines
US4053591A (en) 5-deoxy-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, method for their use as antibacterial agents and compositions useful therefor
US4120955A (en) Method for production of kanamycin C and its derivatives
CS203157B2 (en) Process for preparing aminoglycosides of 2-deoxystreptamine
EP0601909A2 (en) Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof
US4066752A (en) 1-Desamino-1-hydroxy and 1-desamino-1-epi-hydroxy-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols; 1-desamino-1-oxo-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols, intermediates and use as antibacterial agents
US4171356A (en) 2-Unsubstituted derivatives of 4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitois, methods for their use as antibacterial agents and compositions useful therefor
EP0000473A1 (en) Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives
US4212860A (en) 4-O-(2,3,5-Trideoxy-5-amino-α-D-pentofuranosyl)-6-O-aminoglycosyl-1,3-diaminocyclitois, methods for their preparation, pharmaceutical formulations thereof and their use as antibacterial agents
US4140849A (en) Kanamycin C derivatives
US4231945A (en) S-5-(Azidomethyl or aminomethyl)-2-lower-alkoxytetrahydrofurans
US4284764A (en) Process for the preparation of 5-fluoro-5-deoxy and 5-epi-fluoro-5-deoxy-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 5-fluoro-5-deoxy and 5-epi-fluoro-5-deoxy derivatives produced thereby
US3929761A (en) 3-Deoxykanamycin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB NL SE

PUAC Information related to the publication of a b1 document modified or deleted

Free format text: ORIGINAL CODE: 0009299EPPU

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

REF Corresponds to:

Ref document number: 2860513

Country of ref document: DE

Date of ref document: 19810409

18W Application withdrawn

Withdrawal date: 19801220

DB1 Publication of patent cancelled
GBPC Gb: european patent ceased through non-payment of renewal fee
EUG Se: european patent has lapsed

Ref document number: 78100207.6

Effective date: 19820119

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WEINSTEIN, JAY

Inventor name: TATTANAHALLI, NAGABHUSHAN L.

Inventor name: MCCOMBIE, STUART

Inventor name: DANIELS, PETER